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ABSTRACT 
Porcine reproductive and respiratory syndrome (PRRS) is an economically 
significant disease of swine, caused by a small, enveloped RNA virus belonging to the 
family Arteriviridae. PRRS virus preferentially replicates in macrophages and is capable of 
establishing persistent infection. While the mechanism by which PRRS virus persists in 
infected animals is unknown, enhanced infection and replication of PRRS virus in the 
presence of virus-specific antibody has been demonstrated in vitro and in vivo. This 
phenomenon, in which virus-specific antibody facilitates the entry of virus into susceptible 
cells resulting in increased severity of the disease, has been described as antibody-dependent 
enhancement (ADE) of virus infection. ADE also is considered to be a significant obstacle 
to developing effective vaccines for many viruses for which ADE has been reported. In this 
study, the role of specific PRRS viral epitopes in ADE and/or virus neutralization (VN) was 
assessed in vitro, using 18 monoclonal antibodies (MAbs) to 4 PRRS viral proteins: 15kD 
nucleocapsid (N), 19kD matrix (M), 25kD envelope glycoprotein (GP5), and 45kD GP3, 
each of which represents a distinct epitope. One-way ADE and VN assays were performed 
using homologous and heterologous PRRS virus isolates in the presence or absence of each 
MAb. ADE activity was determined by assessing the increase of progeny virus yield in 
porcine alveolar macrophage cultures in the presence of individual MAbs. Neutralizing 
activity was determined by the assessment of reduction or blocking of virus replication in 
MARC-145 cells in the presence of individual MAbs. MAbs could be categorized into 3 
groups: enhancing, neutralizing and neither. Neutralizing epitopes appeared to reside on the 
M, GP3 and GP5 proteins. ADE epitopes were associated with the N, and GP5 proteins. 
Identification of the epitopes responsible for ADE and VN may provide the basis for 
developing efficacious second-generation vaccines for the control of PRRS virus. 
1 
GENERAL INTRODUCTION 
A. Introduction 
As is widely recognized, porcine reproductive and respiratory syndrome (PRRS) is 
an economically significant disease of swine caused by the PRRS virus (PRRSV). In acute 
outbreaks, economic losses from PRRSV have been estimated to range from $236 to $502 
per sow in farrow-to-finish and breeding stock operations 177• In response to the economic 
effects of PRRS, various management strategies and vaccination protocols have been tested 
for controlling PRRS. At present, the definitive solution to the prevention and control of 
PRRS has not been found. A modified live virus (ML V) vaccine and a killed vaccine are 
currently available to swine producers, but it has been observed that PRRS outbreaks occur 
even in vaccinated herds. Several explanations have been proposed to account for this fact: 
1. The currently available vaccines do not induce solid protective immunity; 
2. Field isolates of PRRSV vary genetically and antigenically from vaccine strains to 
the degree that they cannot be controlled by the available vaccines; and/or 
3. Antibody dependent enhancement (ADE) interferes with the protection conferred by 
PRRSV vaccines 246;249• 
Enhancement of PRRSV infection in the presence of antibody is the subject of the 
present study. Antibody-dependent enhancement of virus infection is a phenomenon in 
which virus-specific antibodies actually enhance the entry and possibly the replication of 
virus in monocytes/macrophages and other cells that have Fe receptors on their surfaces 179 • 
ADE has been described for viruses representing 12 different families, including the 
Arteriviridae to which PRRSV belongs 69;89;9o;144;179;246 . These effects are responsible, in part 
or in total, for the difficulties encountered in developing effective vaccines for a wide variety 
of viruses including Aleutian mink disease virus, dengue virus, equine infectious anemia 
virus, feline infectious peritonitis virus, and human immunodeficiency virus type 1 
72;92; 101 ;108;11 4;178 
To minimize the risk associated with ADE in controlling disease by vaccination, 
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efforts have been made to formulate vaccines that induce a balanced immune response or 
minimize ADE 123;144 • The objective of the study was to characterize the role of PRRS viral 
proteins in ADE and virus neutralization (VN) and identify responsible epitopes, as the first 
step towards the development of a subunit vaccine(s) enriched with components associated 
with VN that would offer solid protective immunity against PRRSV. 
B. Thesis organization 
This thesis is organized in three main chapters. The first is the literature review on 
porcine reproductive and respiratory syndrome (PRRS) and its causative agent, PRRSV. 
The second is a review article on the subject of antibody dependent enhancement of viral 
infection to be submitted for publication in Viral Immunology. The third chapter is a 
manuscript of the experimental work on the identification of PRRSV epitopes involved in 
antibody dependent enhancement and neutralization of infection. This work will be 
submitted for publication in Archives of Virology. This thesis also contains a general 
conclusions section followed by the list of references for the first chapter and the general 
conclusions. 
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PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME 
(PRRS) 
A. Clinical presentation and epidemiology of PRRS 
Porcine reproductive and respiratory syndrome (PRRS) emerged late in the decade of 
the 1980' s as a devastating new disease in swine. Several names were given to the disease 
in different regions of the world. Some of those are: mystery swine disease 155 , blue-eared 
pig disease 4;67 , swine infertility and respiratory syndrome (SIRS) 4 1;58 , syndrome 
disgenesique et respiratoire du pore 256 , porcine epidemic abortion and respiratory syndrome 
(PEARS) 174 , and SMEDI-like syndrome 57; 104 • In 1992 it was officially designated PRRS in 
the First International Symposium on SIRS/PRRS, in St. Paul, Minnesota, USA 44;132 . 
The PRRS outbreaks were first recognized in North America in 1987, and reported in 
Germany in 1990 and later in The Netherlands, France, Belgium, England and Denmark in 
1992 4; 12;24;104 . Seropositive herds were also found in Italy and Poland, although virus had not 
been isolated. Korea and Japan have also been affected by this disease 37; 151 ;195 • Currently, 
PRRS is highly prevalent in all pork-raising countries 2;258 
In 1991, the etiology of PRRS was established when a previously unrecognized, 
small, enveloped RNA virus was isolated from animals affected by PRRS in the 
Netherlands. This agent was named Lelystad virus 233 • A virus with similar physico-
chemical characteristics to Lelystad virus was identified later in United States and 
designated ATCC VR-2332 19;46 • Retrospective studies found seropositive samples that date 
as far back as 1984, in the US 146, and 1979 in Canada 30 . Other retrospective studies 
identified seropositive pigs in South Korea during 1985 196 and in Japan in 1988 15 1. 
1. Clinical manifestation 
Clinical signs in pigs affected by PRRS are highly variable in incidence and severity. 
Clinical manifestations also vary with the age of the pig, overall health and vaccination 
status. In general the early signs of PRRS include "flu"-like illness, conjunctivitis, 
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depression, lethargy and inappetence, which can last from a few days to 2 weeks. The 
European Commission (Directorate-General for Agriculture) released, in 1991, the case 
definition for PRRS in breeding stock. This syndrome was defined by an abnormal rate of 
abortion in the late term of gestation, or prolonged parturition producing mixed litters of 
live, dead and mummified fetuses 51 . In pregnant sows, the rate of stillbirths may increase to 
50-70%, in addition to increased abortion rate. Premature farrowing by 5-7 days, poor 
conception rate and slow return to heat are common signs. Infected boars may exhibit 
transient respiratory distress, with subsequent decrease in libido, and in the motility and 
quantity of sperm 45;2 11 • 
In young pigs, the syndrome is presented as respiratory distress. The symptoms may 
vary and can be complicated by secondary respiratory infections. Gastrointestinal or CNS 
symptoms are not usually associated with PRRS 5 1, however, vomiting and diarrhea, and 
CNS signs in experimentally inoculated young pigs have been reported 84;9 1;185 
Affected grow-to-finish pigs usually show mild clinical signs, although, anorexia, 
listlessness, high respiratory rate and fever may be observed. These pigs may have reduced 
growth rates 45 • 
Within an affected herd PRRS can be categorized into subclinical, acute or epidemic, 
and chronic or endemic forms. In the subclinical form the pigs do not show observable signs 
of disease except seropositivity to PRRSV. Both the epidemic and endemic forms of the 
disease show symptoms related to respiratory distress and reproductive failure. The 
epidemic form shows all of the symptoms related to the disease 45;46;51. The duration of the 
epidemic phase can be of weeks to several months 84. An acute form of the disease was 
observed in 1996 in Southeastern Iowa and other states of the Midwest and North Carolina. 
Ten to fifty percent of sows aborted over a 3-6 week period and sow mortality ranged from 
5% to 10% of inventory in a period of one to two weeks 28 • Severe PRRS outbreaks were 
also reported in vaccinated herds in Denmark implicating that current vaccine virus may 
spread through out a naive herd and cause disease 25 . Endemically infected herds may not go 
back to the same production level prior to the outbreak because of continued reproductive 
failure in sows and secondary respiratory infections that prevail in young piglets. 
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2. Prevalence and economic impact 
PRRSV infection is highly prevalent in swine producing regions throughout the 
world except in Sweden, Norway, and Australia 258 • In 1995 the United States' Department 
of Agriculture performed a serologic survey, as part of the National Animal Health 
Monitoring System, to estimate the prevalence of PRRSV infection. The study revealed 
68% prevalence rate, which included vaccinated herds. Prevalence in unvaccinated herds 
was found to be 59% 1• Other researchers report a prevalence of 60 to 80% 259 • 
A nationwide survey in Denmark showed a PRRSV prevalence in finishing herds of 
33% in 1996 147;149 • In the region of Pays de la Loire of France prevalence was estimated to 
be 2.7% a year after the first PRRSV outbreak and after a control program was put to effect 
to avoid introduction of the virus through infected boars, semen used for artificial 
insemination, and possible environmental sources (e.g. contaminated fomites) 115 • In the 
Federal State of Sachsen-Anhalt two wild boars were found to be seropositive for PRRSV 
during the hunting season in 1994 164 • Seropositive rates varying from 8.8 to 67.4% were 
reported in Korea in 1993, however retrospective studies indicate the presence of PRRS in 
this country since 1985 197 • 
The economic impact of PRRS has been calculated to amount losses of $236 per 
female during the acute stage and up to $502 per sow during chronic stage of disease 177• 
This represents a decrease in annual production of 5-20% ( due to slaughtering which 
increases to 10%-15%), and reduction of annual production of 1-1.5, 2-2.5 and 3.8 pigs per 
sow per year 39 • 
PRRS outbreaks also increase other expenses related to production such as diagnostic 
tests, surveillance, and treatment. Treatment to prevent secondary infections can increase 
the production costs by up to 60% 167 . 
In concert with the infertility problems that arise with the persistence of PRRS, 
young pigs fail to thrive, increasing the costs of production. 
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B. Porcine reproductive and respiratory syndrome virus 
1. Taxonomy 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an Arterivirus 
member of the Family Arteriviridae in the Order Nidovirales 32;33 . This order includes one 
more family: Coronaviridae. Among the main characteristics of the order Nidovirales is a 
linear, non-segmented, single-stranded, positive-sense RNA genome, which is expressed by 
a nested set of transcripts sharing the 3' end. The 5' end of the viral genome possesses two 
open reading frames (ORFs) translated by frame-shifting mechanism, which encode for the 
viral replicase. This replicase contains a polymerase and a helicase domain and is upstream 
of structural and non-structural genes that vary in number and kind. Other characteristics 
include the presence of an envelope and polyadenylation of the genomic RNA 32 • 
The Arterivirus family includes equine arteritis virus (EA V), lactate dehydrogenase-
elevating virus (LDV) of the mouse, and simian hemorrhagic fever virus (SHFV), in 
addition to PRRSV 32;48 • The host cell for all the viruses in this genera are macrophages or 
monocytic lineage cells of host species. These viruses also share morphologic and genomic 
similarities as well as the establishment of asymptomatic persistence. 
2. Genomic structure and gene expression 
PRRSV contains a non-segmented, linear, single stranded, positive-sense RNA 
genome of 15 kilobases in length, which is divided into seven (ORFs) 137 • ORF la and lb 
encode for the viral replicase (further described below) and occupies about two thirds of the 
entire genome 133 • ORF2, ORF3, and ORF4 encode minor glycoproteins (GP) GP2, GP3 and 
GP4, respectively, which are postulated to be membrane associated proteins 14;133;137;138 _ 
ORFs 5 through 7 encode the major structural proteins: major envelope glycoprotein (GP5, 
which was previously designated E), matrix (M), and nucleocapsid (N), in that order 139 . 
There have been reports of an additional putative structural protein encoded by ORF2. 136 
and of a smaller ORF- called ORF X- within the ORF5 48 • 
Virus genomic RNA is transcribed through the generation of 6 or 7 subgenomic 
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messenger RNAs (sgmRNAs) by the viral RNA-dependent-RNA polymerase (RdRp) in a 
nested set that share the 3' end 48 . Each one of the sgmRNAs have the same 5' leader 
sequence that is derived from the 5' end of the viral genome 129;134 • Sub genomic mRNAs are 
translated independently 62;135 • 
Expression of the viral replicase polyprotein genes (ORF 1 a and 1 b) is achieved by a 
minus-one (-1) ribosomal frame shifting mechanism which has been described by Allende 
(1999) 10 • This mechanism is very similar to that present in other arteriviruses namely LDV 
and EA V 135 • Various domains including helicase, cystein protease and serine proteases 
have been described for the replicase of PRRSV 10;156;199 • Post-translational self-cleavage of 
the polyprotein produces 12 nonstructural proteins (Nsps) that are responsible for virus 
replication and transcription as demonstrated for EA V 225-227_ 
EAV studies have shown that two non-structural proteins (Nsps) can interact with 
each other and insert themselves in double membrane vesicles in the perinuclear region 
during virus replication. Nsps 2 and 3 contain hydrophobic domains that may allow them to 
localize or embed themselves in the double membrane vesicles 20 1. These proteins are 
involved in the control of proteolysis of replicase precursors and membrane association of 
the virus replication complex. It has been shown that EA V Nsps 1 & 2 are self-cleaved 
quickly after translation 201• Other EAV Nsps in both ORF la and ORFla/b polyproteins are 
cleaved by Nsp4 226 • EAV RdRp domain is found in Nsp9 and the helicase domain is 
located in Nspl0 192 • A metal binding domain was also found in Nspl0 53 • 
Recent studies have demonstrated that PRRSV undergoes genetic recombination 
during infection. Usually defective interfering RNAs (diRNAs) are formed during this type 
of event in high multiplicity of infection (MOI) and are of short duration in persistent 
infection of cells. However, diRNAs were not found for PRRSV 25 1. Further studies 
revealed the production of atypical mRNAs, termed heteroclite mRNAs 134;250 • The 
heteroclite mRNAs are formed by transcription of the 5' and 3' ends of the genome with 
have a large internal deletion and aberrant 5 '-3' junction sites. Heteroclite mRNAs were 
observed both in vivo and in vitro, and could be obtained from virus-like particles. Some of 
these transcripts could produce proteins in frame with ORF6, including one that potentially 
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encodes for a fusion protein of ORFla Nsps with the M protein. Yet, others produce 
relatively short peptides. Their function, if any, remains to be determined. 
3. Morphology and structure 
Porcine reproductive and respiratory syndrome virus is an enveloped virus 45 to 
80nm in diameter with an icosahedral nucleocapsid core about 25-35nm in diameter 62 ;176 . 
The nucleocapsid core contains genomic RNA. The virus may consist of as many as 6 
structural proteins; however, 3 structural proteins, i.e. N, Mand GP5 , have been consistently 
demonstrated 121;139; 148 ;152 _ 
a) Major structural proteins 
GP5 , encoded by ORF5 (603 bases), is 25-26 kilodaltons (kD) and the maJor 
envelope protein. It has membrane signal peptide with a cleavage site between amino acids 
(AA) 32 and 33 for the European strain, Lelystad virus 139, and between 25 and 26 for 
various North American strains 169 • GP5 possesses two putative transmembrane alpha 
helices located between aminoacids 65-130 and 170-190 122;128 ;152 . GP5 also exhibits a highly 
glycosylated putative ectodomain located at the N terminus of the protein 128 . Glycosylation, 
which occurs in heterogeneous and homogeneous forms, containing complex glycans as well 
as high-mannose oligosaccharides or only complex carbohydrates, respectively. 
Glycosylation in PRRSV takes place as a rather slow process in the premedial Golgi 
compartment, compared to its counterpart in EAV and HA protein of influenza virus 121;169 . 
GP5 has been found to possess epitopes related to neutralization of the virus n ;io9;242 . 
Most of these epitopes are associated with, or potentially located in, the proposed 
ectodomain of the protein 23 1• In contrast, Rodriguez et al. reported the presence of an 
immunodominant epitope present at the C terminus of GP5. Even though this region was 
recognized in imrnunoblotting by antisera to PRRSV, its involvement in virus neutralization 
is unlikely since MAbs produced against a recombinant protein containing GP5 AA30-
67 /1 30- 201 did not show neutralizing activity 181 . 
Overall, GP5 shows high sequence variation between North American isolates and 
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the European prototype, Lelystad virus, with only about 55% AA identity 153 ;169 • Aminoacid 
identity ranges from 88-97% among US field strains 128 and 88 to 99% when compared to 
the sequence of a modified live US vaccine strain 153 • Many of the aminoacid differences 
among strains are localized in the hypervariable region of the ectodomain, which comprises 
AA 26 and 39 and was found to be highly antigenic 11 ;169 • 
GP5 also forms heterodimers through a cystine residue with the matrix (M) protein. 
It has been shown that M is bonded to GP5 by a cystine residue located at the N terminus 
end of each protein 12 1;122 • This bonding occurs after accumulation of M protein in the 
endoplasmic reticulum of infected cells and prior to Glycosylation of GP5 12 1. However, like 
for EA V M protein, it can form homodimers early in transcription but which are not present 
in the virion 53 ;120 • These MM dimers function is unknown and fade as M-E heterodimers 
appear 12 1• M is encoded by ORF6 (525 bases); and it is a 19kD non-glycosylated protein 
that has three potential membrane spanning domains 122 ;135 • M has been demonstrated to 
strongly stimulate T-cell proliferation in vitro but the significance of these findings in vivo 
has yet to be studied 16 • 
The core of PRRSV is formed by the capsid, which contains the viral genome. It is a 
non-glycosylated 15kD polypeptide encoded by ORF7 (372 bases) located at the 3' end of 
the genome 14;12 1;122;138; 139; 148 • The capsid protein constitutes about 20 to 40% of the protein in 
a PRRSV particle. A highly negative region in its N terminus is believed to interact with the 
viral RNA, forming the nucleocapsid 75 ;127;138 . Likewise, C termini from different N proteins 
have been shown to interact with each other in a non-covalent fashion to form homodimers 
that would multimerize to produce an icosahedron 240;241 • 
The N protein possesses four regions that are highly conserved, when compared to 
nucleocapsid sequences from all other arteriviruses, perhaps due to functional constraints 113 • 
N has also been reported to have hemagglutinin (HA) activity with mouse erythrocytes that 
can be enhanced by treating the virus with Tween 80 and ether, but was abolished by 
treating the virus with virus-specific antiserum 96 . Mercaptoethanol treatment terminated 
HA activity. Pepsin, formalin and dithiothreitol (DTT) were gradual inhibitors of the HA 
activity by the virus. Fractionation by cesium chloride (CsCl) gradient and subsequent SDS-
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PAGE analysis revealed that this protein co-migrates with the l 5kD nucleocapsid protein 97 • 
PRRSV N protein has been demonstrated to be highly immunodominant since it is 
transcribed in higher levels than other sgmRNAs and consequently translated more, thus, 
antibodies specific to N are produced in high quantities during early humoral immune 
responses, but are non-neutralizing in nature 54;157 • Aminoacid identities of 96-100% 
between sequences from North American isolates and of 94-100% between North American 
and European isolates have been found 127 . For that reason, it has been a major target for 
detection of PRRSV in tissues, as well as major antigen for serological assays. 
b) Minor proteins 
PRRSV ORF4 (537 bases) encodes for a structural glycosylated apoprotein of 20-
35kD depending on the level of N-glycosylation and its localization, i.e. the intracellular 
form is of 20-28kD whereas the virion associated protein is about 31-35kD. Certain 
monoclonal antibodies to LV GP4 (178 AA) had neutralizing activity in vitro but did not 
react with the VR2332 US isolate 140 • The neutralizing epitope was mapped to a region 
comprising AA 40 to 79 which is part of a seemingly hypervariable region of GP4 231 • 
Weiland et al suggested that GP4 antibodies may not be as efficient as anti-GP5 antibodies 
in neutralizing PRRSV since the former required a high antibody titer to have the same level 
of neutralization as anti-GP5 antibodies at high dilution 231 • Nevertheless, in vivo tests 
indicated that immune sera had high antibody titers against GP4 epitopes demonstrating its 
immunogenicity during PRRSV infection 162 • 
GP3 is a highly glycosylated protein that is expressed in similar rate as the N, M and 
GP5 76 . It has been described as a structural protein in the European prototype Lelystad 
virus 136• In contrast, it has not been found in the virion of North American strains, but in 
cell culture supematants at high concentrations 120• Hence, GP3 is considered a non-
structural protein with unknown function 76 . It has been reported that GP3 does not elicit a 
neutralizing antibody response 77 • Its antigenicity is highly variable from one generation to 
the next 113 and to the point of the generation of deletion mutants viruses that outcompete 
their non-deleted counterparts 161• 
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Snijder et al. (1999) found that, in EAV, a region of 76 nucleotides, believed to be 
untranslated, contains the 5' end of an ORF of 201 nucleotides in length, which they 
designated ORF 2a. ORF 2a overlaps the previously described ORF2 (now designated 
ORF2b) which encodes the G5 protein and both are located in the second sub genomic 
mRNA (sgmRNA 2). Homologous genes were also found for other arteriviruses. The 
predicted protein ( 67 AA) is associated with intracellular membranes, was demonstrated to 
be present in purified virions and is essential for virus infectivity 200 . Confirming these 
findings, Wootton et al (2000) also described a second ORF 2 in a Canadian PRRSV isolate. 
This smaller ORF (designated ORF 2b, 222 nucleotides) encodes for a 73AA protein and 
lies within ORF 2a (771 nucleotides) which encodes a 256AA protein. This is the only 
proof ofbicistronic genes in an arterivirus 239 • 
As described earlier the viral replicase is a polyprotein encoded by two contiguous 
ORFs, ORFla (7509 bases) and ORFlb (4371bases) that are expressed by a minus one 
ribosomal frame shifting mechanism. These two ORFs are proposed to encode a total of 12 
Nsps. Nsps la to 8 are encoded by ORFla and Nsps 9 to 12 by ORFlb 239 • The function of 
several of these Nsps is unknown, however, both Nspla and Nsplp contain a papain-like 
cystein protease motif 60 , Nsp2 has a chymotrypsin-like cystein protease, Nsp3 and 5 contain 
hydrophobic domains 202 , and Nsp4 encodes a serine protease proposed to cleave the 
ORFla/b polyproteins 203 ;226• Nsp9 encodes for the RNA-dependent RNA polymerase 
(RdRp) 26, Nspl0 encodes for the helicase protein 53;105 , and Nspll has a Coronavirus-like 
motif 99 . All other Nsps not mentioned here have not been characterized yet. 
Sequence analysis of three independent vaccine-derived PRRSV strains has shown 
that parallel mutations on ORFl helicase and papain-like cystein protease domains were 
reverted to the parental strain 159 • These findings suggest that this polyprotein has an 
important role in virus virulence and/or pathogenesis. 
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4. Characteristics 
a) Tropism for macrophages 
PRRSV exhibits preferential replication in macrophages. Studies using the in situ 
hybridization technique have demonstrated that porcine macrophages from the lung, spleen, 
liver, thymus, lymph nodes and Peyer's patches, and microglial cells are permissive to 
PRRSV so; i73 ;176;2os;229 _ In infected animals 80 to 94% of infected cells collected from lungs 
were alveolar macrophages, although only 2% of the total alveolar macrophag~s were found 
positive 65 . Other porcine cells that can be infected with PRRSV are type II 
pneumocytes2o;ss ;208 and spermatids, however, peritoneal macrophages and bone marrow's 
progenitor cells were reported to be refractive 209 
Although freshly-collected peritoneal macrophages and peripheral blood monocyte 
cells (PBMC) do not support PRRSV replication 64 , cultivation for 24-48 hours can produce 
a low virus yield. Isolation or detection of PRRSV from PBMC has been documented in 
experimentally infected animals 93 • In vitro maturation of PBMCs to macrophages by the 
addition of macrophage colony-stimulating factor (M-CSF), activation by adhesion to 
endothelial cells 229 , or by addition of L929 cell supernatant 213 makes them permissive. 
The use of permissive cell lines has been a breakthrough in the study of PRRSV, 
however very little is known about the viral or cellular receptor required for entry into both 
the natural host cell and/or cell lines. A porcine alveolar macrophage (PAM) membrane 
protein with molecular mass of 210 kD has been postulated to be the viral receptor 63 . 
Monoclonal antibodies (MAbs) to this protein inhibited PRRSV binding to, and infection of 
PAM. However, the same MAbs failed to find the same or a similar protein on a permissive 
cell line (i.e., MA104). Recent studies have reported that PRRSV can attach to certain non-
permissive cells, e.g. rabbit kidney cells, human carcinoma cells, porcine testicular and 
porcine kidney cells, without entry and replication of the virus 219 . This led to speculate that 
another receptor or a yet unknown mechanism was required for the events following 
attachment. Binding studies with various cell types have indicated that, besides binding, 
PRRSV can be internalized through endocytosis into certain non-permissive cells (i.e. Vero 
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cells) and, yet, not cause infection even when the viral RNA is capable of producing 
infectious progeny by itself in the same cell types 106• Endocytosis of PRRSV occurs via 
clathrin pit formation 154 but multiple cellular as well as viral proteins may be needed for 
uncoating of the virus and subsequent infection 106 • 
b) Antigenic variation 
Difficulty in the development of efficacious vaccmes and diagnostic tests, and 
changes in virulence are a few issues that have been attributed to the remarkable genetic and 
antigenic variability demonstrated among PRRSV field isolates 13 1• 
Genetic analyses have shown the existence of at least two major virus genotypes, the 
European and the North American, with extensive genetic variation both within and between 
these genotypes. Nelsen, et al. (1999) found differences between the prototypic North 
American (VR-2332) and European (Lelystad) viruses in the 5' leader sequence and parts of 
ORF la 156 • Marked differences were also found between European and North American 
isolates in some structural genes 102;152 • ORF 7 is highly conserved among North American 
isolates with 95 to 100 percent amino acid homology, but a comparison of North American 
viruses and Lelystad virus found only 57 to 59 percent amino acid homology 128;152 • ORF 6 
is the most conserved gene among North American isolates with up to 100 percent amino 
acid identity and the most conserved between North American and European isolates with 
70 to 81 percent identity 102;127;152 • GP5 , the major envelope protein encoded by ORF 5, 
showed the highest variability among various isolates, which affects the potential level of 
glycosylation 169 • This hypervariability localizes on a highly antigenic region 128 • The amino 
acid sequence homology of GP5 varies from 88 to 97 percent among North American 
isolates and from 51 to 59 percent when comparing North American viruses to the Lelystad 
virus 11;102 ;126 ;152 • ORF2 and ORF4 encoded proteins show antigenic variation 128 • A 
comparison of the Lelystad virus with isolate ATCC VR-2332, the North American 
prototype virus, found an amino acid identity of 63, 58, and 68 % for ORFs 2, 3, and 4, 
respectively 152 • Similar results were reported when comparing the Lelystad virus with U.S. 
isolate VR-2385 145 • 
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Genetic diversity is mirrored by antigenic diversity among PRRS virus isolates. 
Antigenic variation was initially demonstrated in a comparison of European and North 
American isolates. Using an immunoperoxidase monolayer assay (IPMA), Wensvoort et al. 
(1992) evaluated the reactivity of polyclonal porcine antibodies raised against either 
Lelystad virus or North American isolate ATCC VR-2332 with PRRS virus isolates from 
around the world 232 . The investigators were able to differentiate European from North 
American isolates on the basis of differences in IPMA antibody titers. That is, significantly 
higher antibody titers were obtained in the homologous assay system. Later studies found 
even greater antigenic diversity among PRRS virus isolates than initially suspected 13;54;61 ;248• 
Yoon et al. (1995) examined 22 PRRSV isolates from 8 different U.S. states recovered from 
samples collected between 1989 and 1993. Using a panel of 5 MAbs specific for the N 
protein, the 22 virus isolates fell into one of 3 groups based on their reactivity pattern. Yang 
et al. (1999) expanded this study to include 70 North American isolates recovered from 
samples collected between 1989 and 1995 using a panel of 23 MAbs against the N protein. 
These investigators found 5 antigenic groups, with the European Lelystad virus representing 
an antigenic group distinct from any of the North American groups identified 243 • 
Furthermore, using antibodies against discontinuous epitopes of the N and M proteins and 
continuous epitopes of the GP5 and GP3 proteins, the 65 North American isolates in the first 
and second antigenic groups were further subdivided into 9 and 4 antigenic subgroups, 
respectively 242 • Other researchers have also found great divergence between European 
isolates and North American isolates, the major differences are among envelope proteins, 
however N protein presents the lesser diversity and the sharing of two epitopes 55 . A study 
conducted in Korea showed that 92% of the isolates shared a common N epitope, recognized 
by MAb SDOWl 7, with the VR-2332-derived vaccine strain and all isolates were 
categorized as North American genotypes by differential PCR 37 
That field isolates of PRRSV show a remarkable degree of genetic and antigenic 
variability has become abundantly evident. Although the assumption is that these changes 
occur during the course of in vivo replication in swine and arise, in large part, because of the 
errors that occur during RNA replication, the degree and rate of mutation of PRRSV in 
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infected pigs over time is not known. Furthermore no correlation between the severity of 
lesions and genetic differences among the isolates studied has been found 84 • 
c) High inf ectivity 
PRRSV has been found to be highly infectious, i.e. only a minimum infectious dose 
is required compared to other viruses 247 • As little as 101 fluorescent foci units per milliliter 
could establish infection as determined by viremia and seroconversion when the virus was 
given intranasally or intramuscularly. Onset of respiratory symptoms appeared to be 
correlated with challenge dose independent of the route of inoculation; however no link was 
found between the severity of clinical manifestation and virus dose given. Yet, minimum 
infectious dose and clinical effect remains to be assessed for other routes of challenge, as 
PRRS virus is known to establish its infection via many different routes. 
d) Persistence 
PRRS virus produces a persistent infection despite an active immune response 6;83;237 . 
The PRRS virus carrier state was first recognized following transmission of virus from 
animals infected 99 days earlier to commingled sentinel pigs under experimental conditions 
25 7 Subsequently, Wills et al. (1997) reported isolation of virus up to 157 days post 
inoculation 237 . In an experimentally inoculated population, approximately 90% of 
inoculated animals were found to bear the virus at 105 days post inoculation 93 • 
Within herds, three factors contribute to the persistence of PRRSV: infection of sows 
during pregnancy, infected growing pigs and the frequent introduction of seronegative 
animals 39 . Other risk factors include large herd size (>50 sows), total indoor confinement 
and the use of only one building, storage of slurry under floor, lack of disinfecting 
procedures, fumonisin mycotoxin in feed, rodent problems and, possibly, wild bird species 
259 
Passive immunization of piglets with maternal antibodies against PRRSV is an 
important part of maintaining reduced levels of persistence in herds by reducing the number 
of susceptible animals. Chung et al 43 found that piglets whose mothers had low antibody 
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titers had more viremia than piglets nursing from sows with higher levels of anti-PRRSV 
antibodies. So, as the maternal antibodies dwindle between 6 to 8 weeks after birth, these 
piglets become major PRRSV reservoirs in a farrow-to-finish farm setting. 
The exact mechanism(s) by which the virus persists in the host is (are) not known, 
but PRRSV isolates are characterized by a high degree of genetic and antigenic variation as 
reviewed above. Feasibly, persistence in the host and viral diversity could be two sides of 
the same issue. Another possibility was suggested by Allende et al (2000). Their findings 
indicate that PRRSV persists through a slow rate of viral replication that extends up to 150 
days post infection as demonstrated by the presence of negative RNA in examined samples. 
This persistent state could be linked to changes in the glycoprotein (GP3 and GP5) and M 
protein genes 9• Similar observations have been made with LDV, an arterivirus closely 
related to PRRS virus36• Nevertheless, this is an area deserving further studies since 
persistence is an important epidemiological feature that provides a ready means for PRRS 
virus to perpetuate itself through a cycle of transmission from carrier to susceptible animals. 
As a consequence, elimination of PRRS virus from herds is difficult and cyclic bouts of 
PRRS virus-associated health problems are commonplace. 
C. Pathogenesis 
1. PRRSV pathogenesis 
Transmission of PRRSV occurs by direct contact. Once in the pig, the virus binds 
to-, is ingested by- and replicates mainly in macrophages. Binding to alveolar macrophages 
has been shown to occur in a dose dependent manner and reaches a maximum at 1 hour post 
exposure in vitro 154. In vitro studies demonstrated that internalization occurs by receptor 
mediated endocytosis through clathrin coated vesicles 154;185 . Gnotobiotic pigs show typical 
clinical signs upon infection with PRRSV 184 . Edema in infected tissues may be induced by 
the accumulation of immune complexes and consequential attraction of inflammatory cells 
that release vasoreactive cytokines, or by direct vascular damage due to viral replication. 
Viremia that can last up to 8 weeks occurs prior to the development of lung lesions, virus 
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may gain access to the serum via its replication in pulmonary intravascular macrophages or 
pulmonary endothelium 184• PRRSV replicates for a long time in porcine alveolar 
macrophages and can be found in bronchoalveolar lavage fluid (BALF) up to 49 DPI 193. 
Interstitial pneumonia is a lesion commonly observed in pigs infected with PRRSV. 
It consists of the enlargement of the alveolar septa induced by the infiltration of leukocytes, 
principally macrophages. Clinical manifestations such as hyperpnea and dyspnea, 
associated to interstitial pneumonia, correspond to microscopic lesions and high virus titers 
in the lungs of affected pigs. Virus replication on lymph nodes results in hyperplasia and 
necrosis in the germinal centers. Nevertheless, PRRSV replication in lymph nodes is 
transient and limited to a certain cell population of unknown identity 4o;34;35;133;184 . 
Heart lesions have been observed late in infection 46;82 and may be correlated to 
enlargement of the heart 184, however, virus titers are low. Kidney lesions are not commonly 
described for PRRSV infection 206 but, when they occur, can be severe and may be related to 
virulence of the PRRSV strain. In a study conducted by Rossow et al. vasculitis, and not 
necrosis, was observed in kidney at 21 days post exposure with the virus 184. 
PRRSV has also been reported to cause brain lesions 46;84;183;184;2 16• In neonatal pigs 
from PRRSV-positive and vaccinated herds, meningoencephalitis has been observed in the 
absence of other pathogens 185 • Immunohistochemistry of brain tissue revealed PRRSV-
infected macrophages and microglial cells, but other infected cells that did not react with 
macrophage-specific monoclonal antibody were also observed, suggesting the presence of 
other permissive cells. Infection in these piglets may have occurred in utero since fetuses 
per se are susceptible throughout their gestation, but vertical transmission seems to only 
occur during the last trimester of gestation 233 . 12;4o;41 
Study of the expression of macrophage genes induced upon infection is an excellent 
tool to examine virus pathogenesis. Downregulation of the expression of various genes 
including a 2'-5' oligoadenylate (2-5A) synthetase and a putative dual-specificity 
phosphatase was observed using differential display reverse transcription (DDRT)-PCR to 
detect expressed sequence tags (EST) of alveolar macrophages after infection with PRRSV 
230 2-5A synthetase is an intracellular enzyme produced by monocytes, and B and T 
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lymphocytes, and is induced by IL-6, in murine 21 , by IFNP and in much lower levels by 
IFNy, but not by TNF, in humans 238 • Increased expression of 2-5A synthetase promotes 
oligomerization of ATP which activates RNase L, an enzyme responsible for cleavage of 
ssRNA, thus conferring resistance to virus infection 23;35 . 
The upregulation of the expression ofMxl, ubiquitin-specific protease (UBP) 252 , and 
porcine RNA helicase induced by virus (RHIV -1) 253 was demonstrated in alveolar 
macrophages of pigs inoculated with PRRSV. Mxl is member of an IFN-inducible family 
of proteins and is associated with intracellular protein transport 150 • UBP is also associated 
with protein trafficking 254 • In PRRSV infected pigs, transcript levels were highest in lungs 
and tonsils for both Mxl and UBP proteins. However, only UBP was found in higher than 
normal levels in tracheobronchial lymph nodes of affected pigs. These sites are associated 
with persistence of infection in vivo 253 • Elevated RHIV -1 transcript level was also found in 
tissues of persistent PRRSV infection. 
Recent studies by Girard et al. indicate that infection with PRRSV increases the 
secretion of two matrix metalloproteases that aid in the infiltration of lymphocytes, 
macrophages and neutrophils into the lungs. Such proteolytic activity reached its peak 
between 7 to 14 DPI, went down to normal after 42DPI, and was correlated with the 
interstitial pneumonia lesions observed during leukocyte migration 74 • 
Programmed cell death has been proposed to contribute to the pathogenesis of 
diseases induced by various viruses 47;142;220 • Apoptotic activity of PRRSV has been 
associated with the major envelope glycoprotein GP5, in transfected COS-1 cells and 
cultured porcine alveolar macrophages 207 , suggesting that lung lesions characteristic of the 
disease were not caused by necrosis as previously believed 84;182; 184 . Questions on the in vivo 
relevance of this phenomenon led to the investigation of apoptosis in tissues of infected pigs 
2 10 Virus-induced apoptosis was demonstrated in testicular germ cells 209 , lung and 
lymphoid tissues but not always colocalized with infected cells2 10, suggesting that apoptosis 
of the bystander cells could be indirectly induced 198 • 
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2. Factors influencing/contributing to pathogenesis of disease 
a) Immune modulation 
It has been proposed that PRRSV can suppress the development of normal humoral 
and cellular immune responses. Since alveolar macrophages are the host cell for PRRSV, 
the effect of infection on their number and function has been proposed as the principal 
means by which the virus modulates immune responses. The effects of PRRSV infection on 
macrophages and other cells of the immune system are discussed in another section 
(page24) . However, it should be noted that downregulation of antigen expression on both 
alveolar and peripheral macrophages has been observed upon infection with PRRSV, and 
this may be an explanation for the curtailment of virus clearance. Experiments conducted by 
Albina et al to monitor immune responses to PRRSV did not demonstrate systemic immune 
suppression but stimulation. After day 21 post-infection, production of antibodies increased 
and the numbers of leukocytes including CDS+, CD2+ and IgM+ cells were raised 7• Others 
have confirmed these findings and also found decreased CD4+ cell numbers and lower 
CD4+/CD8+ ratios 194 • Despite these observations, the depletion of lymphocytes from 
lymphoid tissues has been reported and proposed to promote susceptibility to secondary 
bacterial infections 4 1;174;182;255 • 
PRRSV infection may affect the lymphocyte responses to other pathogens or 
vaccination against other pathogens 52 . In this study, PRRSV-infected pigs were vaccinated 
against pseudorabies virus (PRV) and their T cell responses were measured after PRV 
challenge. The detection of T cell responses in PRRSV infected pigs was delayed by a week 
when compared to PRRSV-negative pigs. The peak of these responses decreased two weeks 
sooner in PRRSV infected pigs than non-infected pigs. Their study also revealed that these 
responses in PRRSV-infected pigs were not as high as in those infected only with PRV, 
confirming previous findings 7 However, humoral responses against PRV developed 
equally in both groups. 
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b) Difference in virulence 
Differences in virulence among PRRSV isolates have been extensively described 
33;35;234 _ More virus antigen was detected in tissues typically affected by PRRSV, in pigs 
inoculated with highly virulent isolates than with isolates with lower virulence 85 • Virulence 
did not affect the cell types infected or the distribution of antigen in those tissues 85 • In other 
studies, differences in virulence were not linked to the ability of the virus to cross the 
placenta of experimentally infected sows, but to its intrinsic pathogenicity 130;131• 
Variations in the sequences of viral envelope proteins, can result in the development 
of neurovirulence as is the case of Sindbis virus 62 , dengue virus 8 1, certain murine 
retroviruses 180 and encephalitogenic flaviviruses 124 • Sequence analysis of PRRSV strains of 
varying virulence revealed that N and M proteins from US and Canadian strains share 96 to 
100% aminoacid identity as compared with to 57 to 81 % between North American strains 
and European isolates, regardless of their virulence 127 . However, when comparing US 
isolates only, the low virulence strain revealed higher variation in the sequences of ORF2 
and 4 encoded proteins 128 
c) Pig breed 
Susceptibility to PRRSV infection is mostly age-dependent 217 and predisposition due 
to pig breed has been ruled out by some researchers 51• However, experiments using 
Meishan, Hampshire and Duroc pigs demonstrated that Hampshire pigs had more severe 
lesions than the other breeds. Meishan pigs would develop myocarditis and Duroc pigs had 
lower PRRSV-specific antibody titers. Thus, researchers concluded genetic differences 
between these breeds were accountable for the disease level outcome 86 • 
d) Co-infection 
Porcine reproductive and respiratory syndrome is usually complicated due to co-
infection with respiratory tract pathogens. The most commonly isolated secondary 
pathogens during PRRS outbreaks are: Haemophilus parasuis, Actinobacillus 
pleuropneumonia, Streptococcus suis, and Salmonella species. Enzootic pneumonia as well 
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as atrophic rhinitis are other diseases associated with this syndrome 31;183 • 
It is commonly thought that macrophage depletion in lungs or tonsils due to PRRSV 
infection has an effect in predisposing the animals to bacterial infections. In 1995 Cooper et 
al performed studies that could not demonstrate the potentiation of secondary bacterial 
infections (H. parasuis, S. suis, Sa. choleraesuis, and P. multosida) by primary PRRSV 
infection 49 • They postulated that stress due to environmental changes or management, and 
differences in virus strains (some produce different degrees of clinical disease, severity of 
lesions and immunosuppression) as well as chemical and bacterial agents present in the pigs 
system can contribute to the potentiation of infection by respiratory bacterial pathogens in 
field cases. Other investigators also corroborated the lack of a predisposing effect by PRRS 
virus for secondary bacteria such as H. parasuis 190 . 
In contrast, other investigators have been successful in demonstrating a synergistic 
effect between PRRS virus and bacterial agents 205 • Studies performed by Galina et al 73 
demonstrated an increase in the number of animals with suppurative meningitis in pigs 
infected with PRRS virus followed by challenge of S. suis. In utero infection with PRRSV 
demonstrated that piglets become more susceptible to S. suis type II infection 70• Dually 
infected piglets had higher mortality rates (20 out of 22 piglets or 91 %) than single infected 
pigs (1 out of 18, or 5%, PRRSV singly infected, and 5 out of 23, or 21 %, S. suis type II 
singly-infected pigs) and showed reduced numbers of leukocytes, particularly lymphocytes, 
as a result of thymocyte depletion. The thymus in infected piglets were involuted and the 
lymph nodes showed hypertrophy, hyperplasia, necrosis and apoptosis. Bone marrow 
exhibited hypoplasia characterized by a lack of myeloid and erythroid precursors. Dually 
infected pigs not only had higher mortality, but the severity of meningeal disease was 
increased as well. Based on organ lesions, the higher mortality rate and the severity of 
meningitis observed in euthanized infected and control piglets, it was proposed that PRRSV 
infection in utero results in underdevelopment of immune organs and that this predisposes 
the piglets to secondary bacterial infections. 
Due to conflicting observations on the interaction between PRRS virus and bacterial 
agents among studies, a different challenge scheme (i.e. bacteria first followed by PRRS 
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virus inoculation) was explored. Using this approach, Wills et al (2000) investigated S. 
choleraesuis and PRRS virus dual infection with and without stress factors and 
demonstrated synergism between the two agents 236• Singly infected pigs did not exhibit 
clinical signs, but dual-infected piglets and those that were also treated with a stressing agent 
( dexamethasone ), did show severe clinical signs similar to those seen in the field, and had a 
mortality rate of 43%. This group of piglets also shed both PRRSV and S. choleraesuis for a 
longer period of time and the distribution of S. choleraesuis in the tissues was increased. A 
similar approach was applied to studying the interaction between Mycoplasma 
hyopneumoniae and PRRS virus 214 M. hyopneumoniae infected pigs developed more 
severe pulmonary lesions when subsequently exposed to PRRSV. Nevertheless, PRRSV 
primary infection did not influence the course of Mycoplasma secondary infection, except 
that microscopic lesions characteristic of M hyopneumoniae were more severe in these 
animals 2 14• The lack of exacerbation of M. hyopneumoniae infection has also been reported 
before by others 223 . 
Interaction between PRRSV and other viral agents has been studied as well. 
Simultaneous inoculation of pigs with PRRSV and porcine circovirus type 2 (PCV2) 
showed an enhanced distribution and replication of PCV2. However PRRSV infection was 
not different in dually infected pigs from the PRRSV-only infected ones 8• In contrast, 
PRRS virus did not affect clinical signs of swine influenza virus (SIV) infection 175 . Neither 
did it increased the pathogenicity of Pasteurella multosida secondary infection in SIV-
infected animals 31 ;2!5. 
e)ADE 
Independent studies by Yoon and Choi have pointed out the role of antibodies in the 
pathogenesis of PRRSV. Treatment of PRRSV with subneutralizing titers of specific 
antibodies produce increased viral titers both in vivo and in vitro 38;246 . The implications of 
this phenomenon for the maintenance of persistence may be related to the facilitation of 
entry into cells that express Fe receptors on their membranes 66;119;179 . In pigs with low 
PRRSV-specific antibody titers, whether because these are of maternal origin, from natural 
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infection or from vaccination, ADE could be responsible for exacerbation of disease 40;246. 
D. Immunology 
Studying the immune responses to PRRSV has been described as challenging since 
the virus induces unconventional responses and is able to persist in the presence of 
neutralizing antibodies. 
1. Humoral immune response to PRRSV. 
Nelson and colleagues 157 studied the humoral response of intranasally inoculated, 
young gnotobiotic pigs as well as adult pigs. PRRSV-specific antibodies were detected in 
pig sera between 14 and 15 days postinfection (DPI) by immunofluorescence assay. Their 
study also showed that humoral response of adult boars was delayed by a week, since 
detection of antibodies in serum did not occur until 21 DPI. Albina et al demonstrated an 
increase in antibodies in serum beginning on the third week post infection (WPI) up to the 
gth week post infection with PRRSV 7. Several other researchers have reported that anti-
PRRSV antibodies arise between the end of the first through the second week post infection 
98 ;117;157;166;233 ;249 , yet these do not have neutralizing activity 249 . 
In other studies, PRRSV-specific antibodies were detected in serum of 
experimentally infected pigs as early as 5-9 DPI by immunoperoxidase monolayer assay 
(IPMA), and between 9 and 28 DPI by indirect fluorescent antibody (IFA), enzyme-linked 
immunosorbent assay (ELISA) or serum virus neutralization (SYN) assays. Peak levels of 
antibodies were found between 10 and 11 WPI as measured by SYN, but sooner, between 4 
and 6 WPI, by the other assays. Western blot analysis of these sera indicated that an 
immune response to the nucleocapsid protein is mounted first 249 . However studies by 
Loemba et al. 117 have failed to show that the first antibodies produced are specific to the 
nucleocapsid. In their studies they found that antibodies specific to the envelope protein (E) 
appeared at 7 DPI and that anti-15 and -19KD immunoglobulins appeared after two weeks 
post infection. Despite of these differing results, the pattern and onset of the generation of a 
humoral response is in accordance with previous findings. 
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Recent studies in gnotobiotic pigs show that the first immunoglobulins detected, both 
in sera and BALF, were IgM and IgG at 9 DPI. After this point, lgA was detected in BALF 
and increased to a titer of 6 log2 by 14 DPI. This titer was maintained until 35 DPI when it 
started to decline and disappeared by 40 DPI. In contrast, IgA levels in serum peaked to a 
titer of 10.3 log2 at 25 DPI, even when their appearance and disappearance occurred at the 
same time points as for BALF. Only two pigs had neutralizing Abs, one at 35 DPI and the 
other at 52 DPI but remained at low titer levels (1 to 3.6 log2) 110 • 
Neutralizing antibodies to PRRSV were detected between 51 and 70 DPI in 
gnotobiotic pigs that received two subcutaneous inoculations of PRRSV plus Freund's 
adjuvant at 14 and 28 days after the first intranasal inoculation. This study also showed that 
many pigs would produce antibodies specific to both 15 and 19 kD first, but failed to prove a 
correlation between the specificity of the antibody and its time of appearance 157 • 
Neutralizing activity has been associated with GP5, M protein 40;168;249 , and with GP4 228 • 
Despite the high immunogenicity of the N protein, neutralizing activity has not been 
associated with N-specific antibodies 244;249 . 
Epitope mapping studies demonstrated that ORF 4' s protein is immunodominant in 
vivo and that lgA response varies depending on length of viremia. 162 
2. Cellular immune response 
Cellular immune responses to PRRSV infection have been shown to be delayed and 
barely detectable after 3 WPI 125 . Macrophages will be discussed in detail since they are the 
host cell for PRRSV. 
a) Macrophages 
Normal phagocytic activity in macrophages is affected by various factors including 
inflammatory processes in lungs, acute and chronic systemic diseases and air pollutants. In 
the same way, complement receptors (C'R) and receptors to the constant fraction of 
immunoglobulins (FcR) directly influence the effectiveness of phagocytosis. The 
pathogenic and activation states of the macrophages change the receptor density and affinity, 
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respectively. Harmsen et al 87 studied porcine alveolar macrophages (PAM) collected from 
bronchoalveolar lavage fluid (BALF). BALF of healthy pigs is composed primarily by 
alveolar macrophages (AM), lymphocytes and heterophilic cells, which amount for 62%, 
24% and 5% of the cells, respectively. Ninety percent (90%) of AM have FcR and 23% 
have C'R. C'R levels increased when macrophages were activated, however, it was not 
clear if this was an increase in the receptor affinity, the number ofreceptors per cell or in the 
number of macrophages bearing C'R due to chemotaxis. They also found that FcR are 
directly involved in endocytosis of opsonized particles, whereas C'R cannot trigger 
endocytosis by itself, but it does in synergism with IgG. However, their findings 
demonstrate that AM population is heterogeneous, since only some cells could form rosettes 
with opsonized bacteria, others could form rosettes and endocytose, and, yet, some would do 
neither. 
Labarque 11 0 reported that BALF from gnotobiotic piglets infected with PRRSV 
showed increased numbers of macrophage/monocytic cells ranging from 2- to 5-fold from 
9DPI through 52DPI, peaking at 25DPI. Dwindling of macrophage numbers occurred 
between 9 and 20DPI while monocytes and non-phagocytic cells entered the alveolar lumen. 
PRRSV infection can reduce the ability of porcine alveolar macrophages (PAM) and 
pulmonary intravascular macrophages (PIM) to kill bacteria at 24 hours post infection, by 
8.3 and 11.9% respectively, as observed in vivo by Thanawongnuwech and colleagues 216 • 
Their studies also demonstrated that the percentage of bacteria killed was not significantly 
different between experimental and control (uninfected) groups. Also, there was an increase 
in internalization of opsonized bacteria, although this was not statistically significant. There 
was, however, a significant reduction on the production of superoxide anion in both 
macrophage populations after infection with PRRSV. 
Oleksiewicz et al ( 1999) also demonstrated that the phagocytic activity of alveolar 
macrophages is not affected after PRRSV infection in vitro 163 • Alveolar macrophages were 
viable at 24 hours post infection and there were no significant changes in their ability to 
phagcytose after infection with PRRSV; moreover, MHC II production is not affected. 
However, at 48 hours post infection there was 40% fewer macrophages. This cell death was 
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attributed to virus replication and its apoptotic capacity. Despite this, phagocytosis was 
similar to control cells when only considering live cells, whether PRRSV-infected or not. 
These findings support the idea that the dwindling numbers of phagocytes is the lone cause 
for the reduction in phagocytic activity and not to the production of a soluble anti-
phagocytic virokine 100, or virus-induced cytotoxic agent, as seen in Dengue virus infection 
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Macrophages have been shown to exhibit low efficacy in phagocytosing 
Haemophilus. parasuis 189 . Hence, Segales et al propose that PRRSV may indeed activate 
alveolar macrophages instead of causing their demise. Solano et al also proved that 
clearance of H. parasuis is increased early in PRRSV infection in vitro. However, when 
alveolar macrophages of PRRSV-infected pigs were cultured and treated with H. parasuis 
their phagocytic activity was slightly reduced at 168 and 216 hours post infection with 
PRRSV. The macrophages capability of killing bacteria through the production of 
superoxide anion was impaired during this time as well 204 • 
b) Lymphocytes 
An antigen-specific, cell-mediated immune response to PRRSV has been shown in 
pigs following infection. This response was blocked by anti-CD4 and anti-MHC class II 
antibodies 15, and 109was initially detected in virus-infected animals at 4 weeks following 
exposure and continued to be detected through 11 weeks after exposure 15 . ORFs 2, 5 and 6 
products induced higher responses, with M protein (ORF 6 product) inducing the highest 
response 16 . A skin test revealed that infected animals also developed a virus-specific 
delayed type hypersensitivity reaction 15 . 
An increase in the number of CDS+ cells after 21 days post infection of pigs has 
been reported. This increase was observed for three weeks 7 • Shimizu et al also 
demonstrated the increase in CD2+, CDS+ and CD4+ cells preceded by a reduction on the 
CD2+ and CD8+ populations between 3 and 28 DPI. However numbers ofthymocytes were 
not affected throughout the course of infection. They also reported that there was no 
evidence of virus-induced CD4+ cells depletion or mitogenic effect on CDS+ cells, in vitro 
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194 Further in vivo studies revealed that this increase in the number of CDS+ cells is 
localized to the systemic lymphoid tissues, whereas an increase in B lymphocytes is 
observed in lymphoid tissues associated with the mucosa 103 . 
Studies performed with an American strain of PRRSV revealed an increase of 
lymphocyte proportion in BALF of specific pathogen free (SPF) pigs after 21DPI, reaching 
maximum at 28DPI. During this time period (14 to 35 DPI) the macrophage proportion 
decreased and increased after the lymphocytes ratio dwindled 193 . Recent studies 187 confirm 
the findings described above. The overall number of macrophages in BALF does not 
decrease during infection with the European strain of PRRSV (L V) but that the percentage 
of these is affected by the infiltration of lymphocytes. These lymphocytes were of the 
cytotoxic phenotype (CDS+) as well as natural killer (NK) cells and started to show up on 
BALF between 10 to 21 dpi increasing the total number of cells to 10 times its original 
number during this time period. I-helper cells (CD4+ CDS-) or CD4/CD8 double positives 
were not detected among the infiltrated cells. 
Zuckerman et al. (1998) compared the cell-mediated immune response of pigs to 
PRRS virus infection versus vaccination with either pseudorabies (PRV) or PRRS virus 
vaccines using a lymphocyte proliferation assay and the ELISPOT test. The ELISPOT test 
measures virus-specific interferon gamma-producing cells. Infection with a PRRS virus 
field isolate induced a long lasting (> 1 year) and strong CMI response in pigs, which was 
comparable in response to the CMI response following PRV vaccination. In contrast, a 
modified-live PRRS virus vaccine was far less effective at inducing CMI when compared to 
the CMI response arising from a highly protective PRV vaccine. Nonetheless, induction of 
virus-specific cytotoxic I-lymphocytes by PRRS virus infection has not been documented. 
Furthermore, the role of CMI in the control of PRRS virus infection is generally not 
understood 165 • 
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3. Effect on cytokines 
a) IFN 
Buddaert et al. performed both in vitro and in vivo studies to determine the effect of 
interferon alpha (IFNa) on PRRSV replication 27 . When exogenous IFNa was used to 
pretreat cultured alveolar macrophages, PRRSV yield from infected macrophages was 
reduced up to 2.6 loglO TCID50 in comparison with 3.7 loglO TCID50 reduction of vesicular 
stomatitis virus (VSV), a virus highly sensitive to porcine IFNa. The in vivo study, 
demonstrated that primary infection with porcine respiratory coronavirus (PRCV), which 
induces natural IFNa in the lungs, reduced PRRSV yield in alveolar macrophages. Dual 
infection also caused a dramatic increase in IFNa production, compared to PRRSV singly 
infected pigs. In contrast, no effect on PRRSV yield was observed in pigs exposed to 
PRRSV followed by PRCV. Even though PRRSV exhibits low capability to induce IFNa 
production, a secondary infection with PRCV increases total IFNa to a level similar to that 
of a PRCV single infection. The later results are in disagreement with the findings of Albina 
et al. (1998), where PRRSV infection affects IFNa production by secondary infection with 
transmissible gastroenteritis virus (TGEV) 5• 
In vivo studies performed by Meier et al 125 showed that virus specific IFNy 
responses are not detected for the first 9-10 weeks after infection in comparison to IFNy 
response against other pathogens, such as pseudorabies virus (PRV). They found it takes 34 
weeks for the PRRSV-specific IFNy response to reach the same level that a PRY-specific 
IFNy response will attain in two weeks by vaccination. Likewise, the aforementioned 
researchers reported that the addition of IL 12 or the blocking of IL 10 with specific 
antibodies could enhance the IFNy response of PBMC cultures. The addition of ILlO 
suppresses the IFNy production under the same culture conditions. 
Suppression of PRRS virus replication by IFNy as well as type I IFN was also 
demonstrated by other investigators 186 • Their study also showed that IFNy production 
occurs mainly in lymph nodes and lungs of infected pigs, however there may be certain 
populations of infected cells located in lymph nodes and tonsils, that could be resistant to the 
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effects of IFNy during the asymptomatic stage of infection. 
b) Other cytokines 
In dual infection studies with PRRSV and Mycoplasma hyopneumoniae, PRRSV 
infected pigs showed the tendency to have increased expression of IL 1 alpha, IL 1 beta and 
IL8 mRNA 218 . Similarly, other studies have demonstrated the increase in expression ofIL-
1 ~ mRNA in BALF cells from experimentally infected pigs although TNF was not detected 
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4. Maternal immunity 
Very little is known about the role of colostrum-derived immunity in PRRS virus 
infection, and the protection conferred by colostral antibody is presently an area of 
investigation. Specific antibodies have been demonstrated in colostrum from experimentally 
infected sows 68;19 1;232 • Albina et al. (1994) reported that passive maternal antibody was 
detected in the serum of piglets tested 4 days after birth and disappeared by 3 weeks of age 6 • 
In some instances, no maternal antibody was detected in sera of piglets born to infected 
dams. Alternatively, maternal antibody specific for PRRS virus has been reported to persist 
as long as 4 to 10 weeks of age 80;94;160 and occasionally up to 16 weeks of age in pigs nursing 
immune dams 222 • Senn et al. (1998) estimated the mean half-life of maternal antibody to be 
16.2 days (95% confidence interval: 13 .7 - 18.7 days) and 8.1 days (95% confidence 
interval: 6.3 - 10.0 days) for ELISA and SYN antibodies respectively 191• 
Although passive immunity is believed to be protective against infection 43 , passive 
maternal antibodies may play a limited role in preventing infection or decreasing the severity 
of the disease in young animals. Molitor (1993) reported that pigs from non-immune dams 
were not protected following challenge when they were passively given anti-PRRSV 
antibodies, while challenged pigs born to immune dams were protected 143 • Yoon et al. 
(1996) demonstrated enhanced infection and replication of PRRS virus in pigs with 
passively transferred antibody. These observations suggest that antibody alone may not be 
able to protect pigs from disease and that cell mediated immunity might play an important 
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role in protecting pigs from PRRS virus infection. It is known that mammary secretions 
contain high numbers of leukocytes 188 • These cells are absorbed by the neonatal pig from 
the digestive tract and distributed via the lymphatic vessels to the lymph nodes 221 • 
Acquisition of maternal leukocytes by the piglet confers measurable cell-mediated immune 
responses 235 • It is possible, but unproven, that maternal-derived protection against PRRS 
virus infection requires both cell mediated and humoral aspects. 
5. Immunity conferred by natural exposure 
The return of herd reproductive performance parameters to acceptable levels 
following a clinical episode of PRRS is evidence that some type of protective immunity 
develops following exposure. Freese and Joo (1994) investigated 2 herds with a previous 
history of clinical PRRS by serological monitoring and virus isolation 6 months after the 
initial outbreaks and observed that transmission of PRRS virus had spontaneously ceased in 
one of the 2 farms investigated. However, herd immunity against PRRS may be difficult to 
achieve and maintain. Mishchenko et al. ( 1997) reported that clinical signs of PRRS 
recurred in 20 to 30% of sows at 12 to 14 months after recovery 141• 
In individual animals, the development of protective immunity to PRRS virus, 
particularly with respect to reproductive disease, has been shown to occur both in naturally 
and in experimentally infected pigs 17;29;59;71;78;111 ;172;224 • In an experimental challenge study, 8 
gilts were initially exposed intranasally to PRRS virus at 86 to 96 days of gestation and gave 
birth to an average of 5.8 live pigs, 0.6 stillborn pigs, and 2.1 mummified fetuses 79 • Five 
months after initial exposure, the same females were bred and subsequently re-challenged at 
93 days of gestation (7 to 8 months after first challenge). These sows gave birth to an 
average of 10.8 live pigs, 0.5 stillborn pigs, and 0.3 mummified fetuses , indicating that they 
had recovered from the initial infection and had acquired immunity to subsequent 
reproductive losses. Lager et al. (1997) reported that gilts exposed to PRRS virus isolate 
NADC-8 at the time of breeding ( day 0) were protected against homologous challenge, but 
only partially protected against heterologous challenge, at day 90 of gestation. Protection 
against subsequent reproductive losses appears to be of long duration in individual animals, 
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at least against challenge with homologous virus. Experimentally infected sows were 
protected against reproductive losses when challenged with homologous virus as long as 604 
days after the initial exposure 112• 
In endemically infected herds, chronic or cyclic PRRS problems, primarily 
manifesting as respiratory disease in groups of animals, have frequently been reported 
88;95 ;141;206• In individual pigs, several investigators have shown that PRRS virus persists even 
in the face of an active immune response 6; 42; n ; 237; 245• In one study, virus was isolated from 
experimentally infected pigs for up to 157 days after challenge 237 . Benfield et al. (1997) 
were able to detect viral RNA in pigs born to sows challenged with PRRS virus at 80-95 
days of gestation for up to 210 days after birth. Those pigs shed and transmitted the virus to 
commingled sentinels for up to 112 days after birth. These observations raise questions 
regarding the protective role of humoral and/or CMI responses, questions for which we 
currently have no answers 18 . 
6. Vaccine-induced immunity 
In recent years commercial vaccines has been produced and utilized to control PRRS 
in herds worldwide. Currently, vaccines for PRRS are available to swine producers either as 
modified live virus (ML V) or killed products. Vaccination of animals in endemic areas is 
relatively effective for the prevention of reproductive failure 107;11 6;170• Vaccination of boars 
may also reduce shedding of vaccine or challenge virus in the semen, indicating some level 
of protection 42;158;196;2 12 . 
Despite the wide use of commercially available vaccines, PRRS still abides in many 
herds. The efficacy and safety of current vaccines do not appear to be satisfactory. Osorio et 
al. 165 tested both modified live and the inactivated vaccines commercially available. The 
survival percentage was of 50% for pigs vaccinated with the modified life vaccines and 10% 
with the inactivated virus vaccine. Severe outbreaks of PRRS in so-called well vaccinated 
swine operations in southeast Iowa, Illinois, Minnesota, Nebraska and North Carolina has 
been documented 28• ML V vaccine virus is shed in semen of vaccinated boars and may be 
transmitted to na'ive animals and herds 25;42. In some instances, reversion to virulence of 
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modified-life vaccine virus has been demonstrated in herds in Denmark and Canada 25 ;56;118 • 
Sequence analysis of three independent vaccine-derived PRRSV strains has shown that 
parallel mutations on ORFl 's helicase and papain-like cystein protease domains were 
reverted to the parental strain 159 • 
The control of respiratory problems through vaccination appears to be more 
problematic. Recently, the general trend among many USA swine producers and 
veterinarians has been to limit the use of vaccines to the control of clinical outbreaks and for 
use in the acclimatization of purchased seedstock. Recent outbreaks of PRRS in Danish 
herds after the introduction of a modified-live virus vaccine suggest that we know little 
about protective immunity from PRRSV 25 . Observations of this type emphasize the need 
for basic research on the immunobiological properties of viral proteins and their roles in 
immunity and pathogenesis. There are indications of progress in these areas. For example, 
Plana-Duran et al. (1995) reported that PRRS virus neutralizing antibodies were detected in 
pigs inoculated with baculovirus-expressed GP5 protein. Immunization with baculovirus-
expressed GP3 induced even higher protection than immunization with GP5 protein 171• The 
development of "second" generation vaccines such as DNA vaccines is also in progress. 
Kwang et al studied the immune response to various DNA vaccines encoding for PRRSV 
ORF4, 5, 6 and 7 proteins. PRRSV-specific antibodies were detected in 71 % of the 
vaccinated pigs. Cell mediated immune responses were elicited in 86% of vaccinated pigs 
as assessed by lymphocyte proliferation and IFNy production 109;109 • These studies also 
revealed the presence of neutralizing antibodies for both ORF4 and ORF5 envelope 
glycoproteins. 
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ANTIBODY DEPENDENT ENHANCEMENT OF VIRUS INFECTION 
A review paper to be submitted to Viral Immunology 
Sol M. Cancel Tirado 1 and Kyoung-Jin Yoon1•2 
A. Abstract 
In general virus-specific antibodies are considered antiviral and play an important 
role in the control of virus infections in a number of ways. However, in some instances, the 
presence of specific antibodies can be beneficial to the virus. This activity is known as 
antibody dependent enhancement (ADE) of virus infection. The ADE is a phenomenon in 
which virus-specific antibodies enhance the entry of virus, and in some cases the replication 
of virus, into monocytes/macrophages and granulocytic cells through interaction with Fe 
and/or complement receptors. This phenomenon has been reported in vitro and in vivo for 
viruses representing numerous families and genera of public health and veterinary 
importance. These viruses share some common features such as preferential replication in 
macrophages, ability to establish persistence, and antigenic diversity. For some viruses, 
ADE has become a great concern to disease control by vaccination. Consequently, 
numerous approaches have been made to the development of vaccines with minimum or no 
risk for ADE. Identification of viral epitopes associated with ADE or virus neutralization is 
important for this purpose. In addition, clear understanding of the cellular events after virus 
entry through ADE has become crucial for developing efficient intervention. However, the 
mechanisms of ADE remain to be better understood. 
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B. Introduction 
Animals have various mechanisms to prevent invasion of potentially pathogenic 
foreign agents. Due to anatomic location, both gastrointestinal and respiratory passages of 
higher order animals are more likely to come in contact with pathogens. The intricate 
structure of the airways and the presence of physiological barriers, such as mucosa! surfaces 
and cilia in the lumen surface, compose the first line of defense against respiratory 
pathogenic agents. Even when pathogens could overcome these non-specific defenses, and 
reach the innermost branches of the bronchioles and the alveoli, physiologic inflammatory 
responses take place to stop them. Specialized, immune cells called macrophages are 
resident in the alveolar spaces and are capable of ingesting foreign bodies in a non-specific 
as well as specific manner, and destroy them. As proteins of ingested agents are degraded 
by the now activated macrophage, these protein segments or peptides are transported to the 
cell surface to be presented to other cells of the immune system that have been called 
through the production of chemical signals, or cytokines. Among the attracted cells are 
lymphocytes, which are composed of two main populations: T cells and B cells. The T cells 
are divided into cytotoxic T cells (Tc) and helper T cells (TH). The later are subdivided into 
various subpopulations with functions that can be modulated by the cytokines present in 
their microenvironment and by each other. TH cells determine the course of action of the 
overall immune defense strategy, whether it is mainly a humoral response (by antibody 
production) or cellular-mediated cytotoxicity (by Tc)- B cells are responsible for the 
production of specific antibodies, through activation by interaction with T tt· Antibodies are 
especially effective in agglutinating or opsonizing, and neutralizing soluble antigens such as 
bacteria or toxins, but are less so against viruses or other intracellular pathogens. Cell-
mediated cytotoxicity by Tc or other cells such as natural killer (NK) and lymphokine-
activated killer (LAK) cells, on the other hand, play a major role in the clearance of such 
pathogens by killing the infected cells. However a humoral response is important to 
neutralize cell-free and circulating virus during primary infection and plays a central role in 
preventing reinfection by the viral pathogen 85 • 
Despite the efficacy and specificity of the immune system, there are many pathogens 
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capable of evading it and establishing infection that leads to disease. For example, both 
human and murine cytomegaloviruses exhibit resistance to killing by NK cells 134 and 
interfere with the major histocompatibility complex type I (MHC I) antigen processing 2. 
Also, the murine cytomegalovirus can alter surface expression of MHC I molecule 74 . 
Measles virus inhibits interferon (IFN) a and~ production 109 , while Vaccinia virus produces 
an IFN receptor homologue and simultaneously interferes with IFN intracellular signaling 
151
• Other homologues produced are the tumor necrosis factor receptor II (TNFRII) by both 
Myxoma and Cowpox viruses 113 • Cowpox virus can also inhibit interleukin (IL)-1~ 
converting enzyme, which tends to attenuate the acute phase of infection and reduces 
mortality of infected cells providing the virus with more time for production of progeny 
viruses 4 Molluscum contagiosum virus and bovine herpesvirus type 4 each encode a 
protein that prevents receptor-induced apoptosis 162 • Herpes simplex virus inhibits 
complement function, interferes with antigen processing for MHC I presentation, protects 
infected cells from apoptosis and expresses immunoglobulin constant-fraction receptor 
(FcR) homologues that prevent neutralization by complement and antibody-dependent cell-
mediated cytotoxicity 3;37;9 i; i os; i 45 • Human immunodeficiency virus type 1 (HIV-1) also 
utilizes several strategies to evade the immune response. In addition to infect CD4+ 
lymphocytes and macrophages, this virus is capable of downregulation of CD4 and MHC 
class I molecule 95 ;12 1;122 . Latency of HIV infection is achieved by hiding in glial cells 76 and 
resting T cells 29 • HIV can also generate escape mutants i o; i o2;112 , and can cause T lymphocyte 
apoptosis by upregulation of Fas (CD95) and Fas ligand 79 • 
Antigenic variation is another less aggressive but highly effective method by which 
viruses can evade the immune response. Variability in antigenic sites can generate high 
heterogeneity in the viral populations (i .e. quasi-species) even within serotypes 100;146 . 
Epitopes present in one generation of viruses can be altered in succeeding generations, 
making them less immunogenic 80or, can be eliminated through mutations. However, some 
of these mutations could be silent, not affecting neutralizing epitopes 96 • When an antibody 
response specific to a particular epitope on the parental strain is elicited, these antibodies 
will be less likely to confer protection when a second infection with a variant progeny strain 
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occurs 146 . Antigenic variation may also affect the virulence of the virus 103 • Development 
and efficacy of vaccines can be affected by antigenic variation since field strains may have 
evolved and lost epitopes present in the vaccine strain, particularly epitopes associated with 
virus neutralization 88;92;103 . 
Other viruses can utilize preexisting antibodies, which potentially neutralize their 
capability of infecting through their natural receptor-ligand route, and bind to the FcR on 
phagocytes, to facilitate infection of their target cells. These viruses usually can replicate in 
the macrophages or monocytes, and may use them as reservoirs or cellular trampolines in 
order to reach other body tissues. Consequently, increased chance to infect target cells 
results in increased production of viral progeny and often exacerbation of the disease caused 
by them. This phenomenon has been known as "antibody-dependent enhancement" (ADE) 
or "immune enhancement of disease." This review article focuses on those pathogens of 
public health or veterinary importance that are capable of utilizing antibodies to enhance 
their infection, which may result in exacerbation of clinical manifestations. 
C. Antibody-dependent enhancement of viral infection 
Antibody dependent enhancement (ADE) of infection is a phenomenon in which 
virus-specific antibodies enhance the entry of virus, and in some cases the replication of 
virus, into monocytes/macrophages and granulocytic cells through interaction with Fe and/or 
complement receptors 20;5 l ;54; 86;118;128;139 • This phenomenon was first described by Hawkes in 
1964. He reported that it was possible to increase the total yield of a variety of flaviviruses-
including Japanese encephalitis virus, Murray Valley encephalitis virus, and Getah virus- in 
chick embryo cell cultures by first exposing the viruses to high dilutions of homologous 
antibody which was antiviral at low dilutions 6 1. The scientific community considered his 
findings artifacts albeit he could reproduce the results 62 . It was not until 1977 that Halstead 
linked the concept of enhancement with severe dengue disease 57 . 
Subsequent to Hawkes's observation on the aforementioned flaviviruses and some 
arboviruses, ADE has been described for numerous viruses that belong to different families 
and orders. Some examples are: yellow fever virus 148, dengue virus (DV) 56;58 , HIV-1 
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65 ;141 ;156, respiratory syncytial virus (RSV) 40 , Hantavirus 171 ;307, Ebola virus 154 , Getah virus, 
Sindbis virus 2 1, Bunyamwera virus 104 , influenza virus 114; 11 5, West Nile virus (WNV), 
Japanese encephalitis virus B (JEB), rabbitpox virus 61;62 , feline infectious peritonitis virus 
(FIPV) 170, lactate dehydrogenase elevating virus (LDV) of mice, 18;19;69 , reovirus 16, rabies 
virus 82 , murine cytomegalovirus 68 , foot-and-mouth disease virus (FMDV)8, porcine 
reproductive and respiratory syndrome virus (PRRSV) 175 ;27;28 , simian hemorrhagic fever 
virus (SHFV) 123 , and Aleutian disease virus (ADV) of mink. 77 . Some of these viruses 
represent a significant human health threat; yet others are of veterinary importance. 
Common features among the viruses described above are that: a) they replicate, in part or 
exclusively, in macrophages 51;71;97;11 7;117;149;53 ;153;159;166;175; b) they induce the production of 
large amount of antibodies that neutralize, even homologous virus, poorly 7;51;97 111 ;177 and c) 
they cause persistent infections which are commonly characterized by viremia of long 
duration. Antigenic diversity among isolates is also a common feature of these viruses, 
which renders them partially resistant to neutralization by antibodies raised against 
heterologous isolates 51;97;128 • 
D. Mechanism of ADE 
Although the precise mechanism of ADE is not completely understood, it is 
generally assumed that increased yields of virus are primarily due to a greater number of 
susceptible cells being infected.30;40;40;51;77 ;11 7;175 • This increase in the infection rate of cells is 
shown to be mediated by receptors, most notably FcR, which facilitate the uptake of virus-
antibody complexes. However, studies have also suggested that other mechanism(s) could 
also account for increased virus yields. Antibody may also increase the efficiency of virus 
replication, either by facilitating the uptake of infectious antibody-virus complexes or by 
increasing the synthesis of viral protein and nucleic acid. For example, Gollins et al 
demonstrated that antibodies can increase the number of WNV particles attached to mouse 
macrophage-like cells by comparing radioactivity counts associated with cells infected with 
radiolabelled WNV complexed to virus-specific antibodies with counts in the absence of 
antibody 41 ;42 . Robinson et al. demonstrated that replication of HIV-1 was initiated sooner 
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when the virus was pretreated with HIV specific antibodies, as opposed to untreated virus 139 • 
Progeny virus was released sooner from treated cells than from non-treated cells, as well. 
They also found that protein and RNA synthesis were increased in cells that were infected 
with HIV-1 treated with antibody. In contrast, Olsen and Scott studied the kinetics of FIPV 
infection in individual feline peritoneal macrophages in the presence and absence of 
antibody utilizing in situ hybridization 116 • They demonstrated that the number of infected 
cells was increased in the presence of antibody. However, based on the relative intensity of 
radiograms of individual cells, they did not find any evidence that the efficiency of virus 
replication within the cells was enhanced. 
Generally, interaction between virus-antibody complexes and FcR on 
monocytes/macrophages or granulocytes induces signal transduction, resulting m 
phagocytosis, release of cytokines, a superoxide burst, and antibody-dependent cell-
mediated cytotoxicity 143 • These responses are considered antiviral. It is not known how this 
interaction results in enhanced infection. However, since these viruses are known to 
replicate in part or exclusively in these cells, it is assumed they have the ability to modulate 
antiviral mechanisms of the cells either by utilizing their own products or by interfering with 
metabolic pathways of cells. It is also possible that infections by virus-antibody complexes 
are restricted to immunologically immature subpopulations of the cells 51• Halstead and his 
associates found that human monocytes cultured more than 1 day prior to being infected 
with DY-antibody mixture became increasingly less permissive to infection. This loss of 
permissiveness may have been due to increased lysosomal activity 56;57 • These observations 
explain why high virus titers are produced in bone marrow explant cultures in which young 
monocytes are continuously produced 51 • Restriction of virus infection to immunologically 
immature cells was also demonstrated in mice that were persistently infected with LDV 152 • 
1. Antibodies mediating ADE 
Enhancement of virus infection has been demonstrated usmg vanous sources of 
antibodies. These sources include polyclonal antisera generated in natural host or other 
animals, mouse ascitic fluids containing MAbs to the virus of interest, and immunoglobulins 
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isolated from antiserum. The mechanism by which ADE is mediated is known to be 
primarily through the interaction of the Fe region of virus-specific IgG and Fe receptors on 
the surface of monocytes/macrophages and granulocytic cells56;11 8;127 • Halstead and 
O'Rourke fractionated IgG and IgM from antisera of DY-immunized monkeys and 
evaluated which fraction increased the yield of progeny virus 56 • Enhancement was observed 
only with the IgG fraction, while virus that was exposed to the IgM fraction was neutralized. 
Similar observations were made by Olsen et al. who evaluated the ability of mouse MAbs 
specific for the spike (S) protein of FIPV to mediate ADE in feline peritoneal macrophages 
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• Only IgG class MAbs enhanced FIPV infection, while IgM class MAbs did not mediate 
ADE. To date, it is not known whether or not other subtypes of antibodies (IgA, IgD and 
IgE) can mediate ADE. 
Different isotypes (subclasses) of IgG have also been evaluated for their ability to 
mediate ADE. In the case of DV, murine IgG 1, IgG2a, and IgG2b monoclonal antibodies 
specific for the E envelope protein of DV serotypes 2 and 4 are reported to enhance infection 
of the virus when cells with compatible Fe receptors were used as targets 63 ;107 • No 
information is available about the role of IgG3 in ADE of DV infection. In contrast, Corapi 
et al. evaluated the ability of 19 mouse monoclonal antibodies specific for the S envelope 
protein of FIPV to induce ADE in feline peritoneal macrophages.30 . All MAbs were capable 
of neutralizing the ability of virus to infect a permissive cell line. Fifteen of 19 MAbs 
induced ADE of infection in macrophages and all but one were of the IgG2a subclass. The 
remaining 4 MAbs that did not induce ADE were IgG 1. The difference in the isotypes 
between neutralizing MAbs that induced ADE and those that did not induce ADE suggested 
that there might be a restriction in the subclasses capable of mediating ADE. It is also 
possible that the difference in the ability of FIPV-specific murine IgG isotypes to mediate 
ADE is due to differences in the binding affinity of murine isotypes to FcR on feline 
macrophages 64 . The ability of the different isotypes of human and other mammalian IgG to 
enhance virus infection has not been evaluated. 
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2. Receptors involved in ADE 
Several cell surface molecules, including the FcR, complement receptor (CR), ~2-
microglobulin, and some "Cluster Designation" (CD) molecules, have been reported to play 
a role, or at least to be involved, in mediating ADE of virus infection 86;97 . Antibody-FcR 
interaction is known to play a key role in ADE. The FcR-mediated mechanism of ADE was 
first suggested by Halstead et al. who reported that F(ab')2 fragments prepared from IgG did 
not enhance infection of DV in human peripheral blood leukocyte cultures while whole IgG 
did so 56 • This was indirect evidence which suggested that interaction of virus-IgG 
complexes with FcR on the cell surface may be necessary for ADE of virus infection. Other 
indirect evidence for this interaction was shown by Daughaday et al. 31 . These investigators 
found that ADE of DV infection in monocytes was inhibited by first treating the cells with 
immunoglobulin specific to cellular receptors prior to exposing cells to virus-antibody 
mixtures. Yang et al. has shown that antisera specific for DV serotype 1 (DV-1) can 
neutralize DV-2 infection into BHK-21 cell line but does not neutralize infection of human 
monocytes 173 . Peiris et al. conclusively demonstrated that the interaction between virus-
antibody and FcR is essential for the ADE of virus infection 118 • They were able to block 
ADE of WNV infection in a macrophage-like cell line (P388Dl) by pretreating the cells 
with anti-FcR MAb prior to exposing cells to a virus-antibody mixture. Other investigators 
were also able to block infection of cells by virus-antibody complexes by first treating virus-
antibody mixture with Protein A which binds to the Fe portion of antibody 77;117 • Necessity 
of FcR in ADE of virus infection was also demonstrated by the observation that FMDV 
complexed to antibody could infect an engineered cell line expressing murine FcyR which 
otherwise would not be permissive to the virus. 98 Similarly, a human cell line (K562) 
expressing FcR, normally is not permissive for ADV, supported viral replication when the 
cells were exposed to ADV complexed to antibody 34 • 
In humans, there are 3 types of Fe receptors which bind human IgG: FcyRI, FcyRII, 
and FcyRIII 6;133 164 • The FcyRI is present exclusively on monocytes/macrophages and binds 
human IgG with high avidity. It has higher specificity for IgG 1 and IgG3 isotypes than for 
IgG2 and IgG4 isotypes. The two other receptors, FcyRII and FcyRIII, are found on 
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monocytes, macrophages, eosinophils, neutrophils, natural killer cells, B lymphocytes, and T 
lymphocytes. These two receptors have relatively low avidity for IgG compared to FcyRI. 
Kontny et al. showed that FcyRI mediated ADE of DV infections in U937 cells 84 • In a 
related study, FcyRII was also reported to mediate ADE of DV infection in a human 
erythroleukemic cell line (K562), which has only FcyRII 90• The role of FcyRIII in ADE of 
DV infection is not known. 
Mouse macrophages are known to have two types of Fe receptors, designated FcRI 
and FcRII, which bind IgG. The FcRI is trypsin-sensitive and binds IgG2a, while the FcRII 
is trypsin-resistant and binds IgG2b and IgG 1 complexes 33 . Peiris et al. studied the 
inhibitory effect of anti-mouse FcRII antibody on the ADE of WNV infection mediated by 
anti-WNV MAbs of subclasses IgGl or IgG2a 118 • Pretreatment of P388Dl cells with anti-
FcRII antibody completely inhibited enhancement of virus infection mediated by both IgG 1 
and IgG2a anti-WNV MAbs. Enhancement of WNV infection, however, was independently 
achieved with anti-WNV MAbs of both subclasses. Other investigators found that intact 
anti-FcRII antibody interfered with both FcRI and FcRII in a macrophage rosetting assay 163, 
suggesting that both Fe receptors on mouse macrophages can mediate ADE of virus 
infection. 
Since ADE of virus infection results from the interaction of virus, antibody, and FcR, 
changes in any of these three components may modulate the ADE. Of the three components, 
the FcR can be most easily modulated in vitro within relatively short periods of time by 
treating FcR-bearing cells with certain cytokines or proteolytic enzymes. A quantitative 
(i.e., number) change or a qualitative (i.e., avidity for Fe portion of IgG) change in FcR 
expressed on cells may influence the ADE of virus infection. For example, gamma 
interferon (IFNy) is known to increase the number of FcyRI without changing in the affinity 
of each FcyRI for the Fe portion of IgG 119;144 • Kontny et al. reported that pretreatment of 
human monocytic cells with IFNy augmented ADE of DV infection and that the level of 
enhancement correlated with the increase in the number of Fey RI on the cells 84• In another 
case, Halstead and O'Rourke found that pretreatment of monocytes with pronase, trypsin, 
and protease augmented ADE of DV infection 56 • Zoellner et al. have also suggested that 
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protease may play a role as a cofactor in ADE of HIV infection 178 • More recently, Mady et 
al. examined the effects of neuraminidase on ADE of DV infection mediated by the low-
affinity FcyRII in vitro 94 . They found that neuraminidase treatment of the K562 cells that 
have only FcyRII increased the degree of ADE of DV infection by human anti-DY 
antibodies. It i~ known that treatment of FcyRII with enzymes such as pronase, trypsin, 
elastase, and neuraminidase increases the avidity of receptors for IgG but does not increase 
the number of the receptor expressed on cell surface 32; 165 • 
Besides FcR, complement receptors have also been implicated in ADE of virus 
infection 20;142 • Cardosa et al. found that infection of P388D 1 cells by WNV is enhanced in 
the presence of virus-specific IgM by supplementing fresh mouse serum containing 
complement to virus-IgM mixtures prior to inoculation.20 However, the magnitude of 
enhancement of WNV infection mediated by complement was less than IgG-mediated ADE 
of virus infection. Complement-dependent ADE of HIV infections has also been reported 
44;75; i o5;140;142 • Subneutralizing levels of HIV-specific antibody enhance virus replication in 
several human neoplastic cell lines that express CR and CD4, as well as FcR, in the presence 
and the absence of complement. The magnitude of the enhancing effect was greater in 
complement-mediated ADE of HIV replication than enhancement mediated by the presence 
of antibody only97• Furthermore, Robinson et al. reported that replication of HIV was 
initiated sooner and the efficiency of replication (e.g., protein and RNA synthesis) was 
enhanced through the mechanism of complement-mediated ADE 139 • 
Several cell surface molecules are known to enhance virus infections or to be 
involved in ADE 93 ;97 • Takeda et al. demonstrated that ADE of HIV infection in monocytic 
cells via FcR was blocked by pretreatment of cells with monoclonal antibodies to CD4 
molecule, as well as to FcyRI 155 • Robinson et al. also reported that enhanced infection of 
HIV through complement-mediated ADE required not only complement receptors, but also 
CD4 molecules on the surface of cells142 • These observations indicate that the presence of 
the CD4 molecule on the cell surface may be a requirement for both the FcR-mediated and 
complement-mediated ADE of HIV-1 infection. In the case of DV infection, Mady et al. 
used bispecific antibodies which were prepared by chemically cross-linking anti-DY 
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antibodies to antibodies specific for one of three Fe receptors or non-FcR molecules, and 
demonstrated that DV infection could be enhanced by non-FcR molecules such as ~2-
microglobulin, CD15 or CD33 93 • 
The critical role of natural viral receptor(s) on the membrane of target cells in ADE 
1s uncertain. Chinese hamster ovary cell line engineered to express murine FcyR was 
permissive to FMDV coupled with antibody whereas it was not permissive to poliovirus-
antiVP 1 antibody complexes. This lead investigators to the conclusion that the natural 
receptor for FMDV is only involved in attachment and not in subsequent steps of replication 
such as uncoating 98 . This conclusion was ratified when FMDV with mutated RGD 
sequences of the G-beta H loop of VPl protein of the nucleocapsid was unable to bind 
susceptible cells. However, when these mutants were complexed with antibody against the 
VPl protein, virus infection was established in the cell line expressing FcyR on the cell 
membrane, revealing that the mutations only affected the binding capability of the virus. 
From these observations, one can speculate that naturally occurring mutations during 
infection could be bypassed in the presence of antibodies specific to epitopes from this 
receptor protein and would enhance infection instead of neutralizing it. 
3. Viral proteins/epitopes associated with ADE 
Viral antigenic determinants associated with envelope protein(s) induce antibodies 
which mediate ADE 17;3o;4o;63 ;11 7;136;157 . Scott and his associates conducted extensive studies 
utilizing monoclonal antibodies specific for the nucleocapsid protein, matrix protein (M), 
and the S protein of FIPV. ADE-associated epitopes were only found on the S protein30;117 . 
More recently, an in vitro experiment using vesicular stomatitis virus (VSV) vector 
expressing surface glycoprotein of Ebola virus (Zaire strain), which is associated with cell 
penetration, demonstrated that antibody generated against this protein could enhance 
infection of the VSV vector and of a less virulent strain, Ebola-Reston in human kidney 293 
cells 147 . The same observations have also been made for envelope proteins of other viruses 
for which ADE has been reported. Specific examples are: the E protein of DV 63 , gp120 and 
gp41 of HIV 1;32; 137; 138 , HA protein of influenza virus 11 5;157, G 1 and G2 proteins of hantavirus 
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174
, and the F protein of RSV 40• 
To date, no internal proteins of enveloped viruses, for intact viruses, have been 
reported to be associated with the induction of enhancing antibody, with the exception of 
pre-M protein, an immature matrix protein of dengue virus 63 • However, it is plausible that 
completely or partially naked virus containing infectious genetic material could establish 
infection and replicate in a target cell if it is internalized through antibody-FcR interaction 
(i.e. ADE), as is the case for transfection of infectious viral RNA to non-permissive cells 66 . 
Reovirus is the only non-enveloped virus for which ADE was reported. Enhancement of 
reovirus infection in the P388Dl cells was demonstrated to be mediated mainly by 
monoclonal antibodies specific for the cr-1 protein, a major outer capsid protein which 
determines the serotype ofreoviruses 17• In addition, monoclonal antibody specific for other 
capsid proteins, such as µ 1 c protein, was also reported to mediate the ADE of reovirus. No 
protein of the inner capsid of reovirus was found to be associated with ADE. 
Since viruses in the same genus or family may share common antigenic 
determinants, ADE of virus infections can be mediated by antibodies raised not only against 
heterologous strains but also different serotypes of the viruses or even against closely related 
viruses in the same genus or family. This observation suggests that enhancing antibodies 
may not be highly specific for a specific virus. For example, studies using polyclonal 
antibody revealed that DV infection can be enhanced by antisera raised against heterologous 
serotypes of DV and also by antisera specific for other flaviviruses, suggesting that not only 
serotype-specific but also serotype- and flavivirus-cross reactive epitopes are associated with 
ADE 56 48;59 • There was a difference in the magnitude of enhancement mediated by 
homologous sera as compared to heterologous sera. A similar observation has also been 
made utilizing monoclonal antibodies 13;59;63 ;107 . These studies revealed that infections of DV 
type 2 (DV-2) could be enhanced by monoclonal antibodies directed against heterologous 
DV-2 isolates and against DV type 4. Likewise, Tamura et al. found that infection by 
influenza A virus was augmented by pretreating the virus with antisera raised against 
different subtypes of the virus 158 . In the case of FIPV, virus infection in feline peritoneal 
macrophages was enhanced by monoclonal antibodies generated against transmissible 
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gastroenteritis virus (TGE) of swine which, like FIPV, belongs to the family Coronaviridae 
116
. A similar observation was made with African flaviviruses, such as West Nile, Zika, 
Wesselsbron, Dakar bat, Potiskum, Uganda S, and yellow fever viruses 35 • For example, 
anti-Potiskum virus antibodies enhanced other flaviviruses but most of antibodies to the 
other flaviviruses did not enhance infection of Potiskum virus (in mouse macrophage like 
cell line, P388D). On the contrary, all heterologous antibodies enhanced West Nile, Uganda 
S, Wesselsbron and Zika viruses. Moreover, homologous antibody induced higher levels of 
ADE of virus infection (as calculated by enhancement ratio of virus plaque counts) than 
heterologous antibody 59 • This could be related to the amount of "enhancing" epitopes 
shared among species. Cross enhancement could have important epidemiological relevance 
in areas where these viruses are endemic since cross-reactive "enhancing" antibodies permits 
co-existence of multiple serotypes in the population and promotes their persistence 36 • 
Since antigenically distinct strains of virus may have different quantitative and/or 
qualitative profiles of epitopes associated with ADE, differences in epitopic profiles may 
influence augmentation of virus infection in the presence of antibodies directed against 
heterologous strains or viruses. Consequently, strains vary in their susceptibility to ADE 
and/or ability to induce ADE 97;106 • Halstead and others evaluated anti-DY sera from 
naturally infected humans or produced in various species of animals (mouse, rabbit, 
monkey) against 4 different serotypes of DV for their ability to cross-neutralize DV-2 and to 
mediate ADE of DV-2 infections 56;59;106;107 • Their studies revealed that heterotypic antisera 
poorly neutralized DV-2 infectivity for continuous cell lines, but both homotypic and 
heterotypic antisera enhanced DV-2 infection in human peripheral blood leukocyte cultures. 
The degree of ADE of DV-2 infection mediated by either homotypic or heterotypic antisera 
varied. Higher ADE activity for DV-2 infection was detected in the heterotypic antisera, 
most notably DV-1 antisera, than in the homotypic serum. Moreover, the magnitude of 
maximum ADE of DV-2 infections mediated by heterotypic antisera varied among the 
antisera, as well as the serum dilution at which the maximum ADE activity for DV-2 was 
observed. These results suggested that DV serotypes and field isolates varied in their 
susceptibility to ADE mediated by antibody raised against heterologous serotypes or 
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isolates, and probably also varied in their ability to induce enhancing antibodies. The 
variability in ADE response among the DV-2 isolates was attributed to differences in the 
epitopic profiles of the isolates. A difference in the susceptibility to ADE among isolates 
has also been reported for the porcine arterivirus, PRRSV. Investigators demonstrated that 
some isolates produced higher progeny virus titers than others when inoculated to porcine 
alveolar macrophages after treated with the same PRRSV antiserum 176 • 
In similar studies with FIPV, Olsen et al. evaluated the biological function of MAbs 
raised against the S protein of the virus and discovered that specific epitopes of the S protein 
vary in their ability to induce ADE-associated antibodies 11 7• They were able to categorize 
the monoclonal antibodies that represent the epitopes of the envelop S protein into 3 groups 
according to their ability to: a) only neutralize, b) both neutralize and enhance, and c) only 
enhance FIPV infection. Furthermore, monoclonal antibodies with specificity for different 
FIPV antigenic determinants varied in their ability to enhance virus infection, suggesting 
that epitopes are either strongly or weakly associated with ADE 30;117 • These finding are 
particularly noteworthy because they suggest that it may be possible to develop vaccines 
with strong neutralizing and weak ADE inducing characteristics. HIV-I isolates similarly 
vary in their susceptibility to ADE and/or in the ability to induce enhancing antibodies . It is 
believed that susceptibility is due to the great genomic diversity that has been demonstrated 
among HIV isolates 97 • Currently, variation in the susceptibility of isolates to ADE and in 
the ability to induce ADE are of great concern for developing vaccines against viruses for 
which ADE and antigenic diversity have been reported. 
4. Cellular events 
It has been shown that for some viruses binding is not sufficient for infection, 
suggesting the involvement of other viral and host cell proteins in the internalization process 
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• In such cases, the presence of antibodies that prevent binding will not neutralize but 
facilitate infection, as seen with attachment-defective FMDV mutants 99 • Thus, 
internalization may occur through other pathways instead of the endocytic pathway, 
commonly attributed to enveloped viruses 43 ;110 . However, it has also been shown that the 
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presence of enhancing antibody does not affect the internalization pathway of WNV 42. 
While enhanced entry and increased production of virus is documented in association 
with ADE, it is not well understood how cells like macrophages, whose internal 
microenvironment should be antiviral, become favorable to virus replication when ADE of 
viral infection occurs. Some limited studies have suggested that virus entry by ADE follows 
a pathway which may modulate normal immune functions of infected cells such as 
macrophages. In an early study with DV, the production of high level of prostaglandin E2 
(PGE2) but not IL-4 from peripheral mononuclear leukocytes was observed when the cells 
were inoculated with DV-2 pre-treated with DV-1 antiserum 25 • The PGE2 is a lipid 
cytokine produced by macrophages that has anti-inflammatory properties and is responsible 
for increasing the production of IgG2 in humans 70 • In bovine, PGE2 also has important 
regulatory functions in type 1/type 2 immune responses and can regulate virus expression 
and disease progression in BL V infection 130. 
A recent study by Lidbury et al (2000) has brought some insight to the cellular 
events of ADE when they studied Ross river virus (RRV), the causative agent for epidemic 
polyarthritis 89 . When murine macrophages were infected with RRV through antibody-FcR 
interaction instead of the natural viral receptor on the cell, LPS stimulation of cells did not 
produce successful antiviral response. Instead, the production of IRF-1 and NF-kappaB 
transcription factors for antiviral genes such as TNF and inducible nitric oxide synthase 
genes was inhibited. Thus RRV replication was not affected. Despite this, transcription of 
cellular genes unrelated to antiviral activity and overall mRNA translation was not 
downregulated. 
E. Biological significance of ADE 
1. Disease enhancement 
Antibody dependent enhancement of virus infection has been suggested as a disease-
enhancing factor for several human and animal viral diseases 97 . Specific examples include 
Aleutian mink disease virus, dengue virus, feline infectious peritonitis virus, and respiratory 
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syncytial virus 22;23 • In addition, ADE has also been implicated as a major obstacle to the 
development of vaccines for such viruses as ADV 125 , bluetongue virus 15, DV 12, FIPV 167, 
influenza virus 169 lentiviruses 10 1;168 measles virus 14. 132 rabies virus 150 and RSV 78 In all 
' ' ' ' . 
cases, the presence of antibodies induced by vaccination increased the susceptibility to 
subsequent virus infections and/or exacerbated the severity of clinical disease by virus 
challenge in vaccinated individuals. 
a) Dengue virus 
Dengue viruses belong to the genus Flavivirus of the family Flaviviridae. There are 
4 serotypes: DV types 1, 2, 3, and 4 49 . Dengue virus infections are considered a serious 
human health problem in many areas of the world. Dengue virus infection can be 
asymptomatic or cause two forms of disease 49 • In most cases, DV infection causes a febrile 
disease referred to as 'dengue fever', which is characterized by fever, retro-orbital pain, 
muscle aches, bone pain, and petechiae. Patients recover in 7 to 10 days without 
complications. In some instances, patients infected with DV leak plasma into interstitial 
spaces resulting in hypovolemia and, sometimes, circulatory collapse. This severe and life-
threatening syndrome, which is always accompanied by thrombocytopenia and sometimes 
by frank hemorrhage, is termed dengue hemorrhagic fever (DHF). More severe clinical 
manifestations of DHF in which plasma leakage is so profound that shock occurs, are 
referred to as dengue shock syndrome (DSS). 
Although the pathogenesis of DHF/DSS is not clearly understood, the association 
between ADE and the severity of disease has been extensively studied. This association was 
first described by Halstead and co-workers who observed that the severity of dengue fever 
was significantly greater in children with maternal antibody specific for DV than in children 
with no DY-specific maternal antibody 45;5o;55 . Experimentally, these investigators 
demonstrated in rhesus monkeys that anti-DY maternal antibody enhances DV infection 47• 
The Investigators injected monkeys intravenously with small amounts of human cord blood 
containing anti-DY antibody and immediately challenged them with DV. The monkeys that 
were injected with DV antibody developed higher levels of viremia for a longer period than 
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control monkeys. In a clinical setting, sequential infection models demonstrated that a 
patient who had previously been infected with either one of the four DV serotypes, and was 
subsequently exposed to DV-2 had a greater risk to develop DSS. The risk for severe form 
of DV infection was reported to be the highest when the infections were of the DV-1/DV-2 
sequence 25 • 
It was also found that DV produced a more severe clinical manifestation in older 
individuals who had subneutralizing levels of antibodies, which were induced by previous 
DV infections than in individuals who had no previous exposure to the virus.49;52 . These 
severe clinical manifestations were more frequently observed in individuals who have 
antibody against one serotype of DV and were subsequently exposed to a different serotype 
of DV than in individuals challenged with a homologous serotype. Recent prospective case-
control studies conducted by Burke et al. 16 and Kliks et al. 83 demonstrated that presence of 
DV antibodies is a significant risk factor for increased severity of disease by subsequent DV 
infection. In these studies, individuals were categorized into the case and control based on 
the presence and absence of anti-DY antibody. Decay of DV antibody was monitored for 
the case group and correlated to ADE activity in undiluted sera. Both groups were also 
monitored for subsequent clinical event with respect to natural DV infection. The 
investigators observed that the morbidity of DV infection was significantly higher in the 
case than the control. Mortality due to DHF/DSS was also higher in the case group than the 
control. 
b) Respiratory syncytial virus 
In general, RSV infections are not always considered serious. However, individuals 
who develop pneumonia from RSV infection often require hospitalization. Chanock et al. 
reported that naturally acquired severe RSV infections were almost always seen in the first 6 
months of life when children had circulating maternal anti-RSV antibodies 24 • In another 
study, infants with maternally acquired RSV antibody not only were susceptible to RSV 
infections, but the rate of severe disease was higher in these infants when compared to 
infants without maternal antibodies 23 . These observations led to speculation that RSV-
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specific antibody may contribute to the severity of clinical manifestations of disease caused 
by RSV. A recent study demonstrated that infection of a mouse macrophage cell line by 
RSV is enhanced in the presence of virus-specific antibody 40• This observation supports the 
hypothesis that immune-mediated enhancement of disease does occur in human RSV 
infection and may contribute to the pathogenesis of the disease. 
Immune-mediated enhancement of disease has also been described in human infants 
and children vaccinated against RSV. Several epidemiological and experimental studies 
found that immunization with an inactivated whole virion RSV vaccine led to development 
of antibody response, but did not prevent infection with wild-type RSV in children less than 
2 years of age 26;39;73 ;3 1• More importantly, subsequent natural infection by wild-type RSV 
resulted in an extremely high frequency (52-69% of infected children) of severe lower 
respiratory tract disease (i.e., pneumonia) in the vaccinated group, whereas only 9-10% of 
infected children became pneumonic in the non-vaccinated group78;8 1• Furthermore, the 
duration of illness was longer 39 and the severity of illness was greater in the vaccinated 
children compared with non-vaccinated children 26 . Results from these studies indicated that 
children were at increased risk of severe RSV disease following immunization. Similar 
observations were also made with measles virus. Natural infection with measles after the use 
of the killed measles virus vaccine produced a severe systemic disease characterized by 
pneumonia, unusual rash and edema 38 . 
c) Feline infectious peritonitis 
Feline infectious peritonitis virus is a coronav1rus that causes peritonitis and 
occasionally a fatal pyogranulomatous disease in kittens and cats 171;172 • Antibody dependent 
enhancement has been incriminated as a disease-enhancing factor of feline infectious 
peritonitis 120; 170• Cats with active or maternal immunity to FIPV often develop an 
accelerated and more fulminant disease following challenge with FIPV than seronegative 
cats. The role of antibodies in mediating more severe disease following challenge has been 
also documented in cats that were injected with FIPV-reactive immune sera or purified 
immunoglobulin and subsequently challenged with the virus 170 . Furthermore, immune-
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mediated disease enhancement has been demonstrated in kittens who had vaccine-derived 
humoral immunity directed against the spike protein of FIPV. These kittens died earlier 
than did control animals 167• Similarly, kittens immunized with a recombinant vaccinia virus 
expressing the spike protein of FIPV died earlier than control animals 167• 
d) Aleutian mink disease 
Aleutian disease virus is a parvovirus that circulates in the blood principally as 
immune complexes, which are fully infectious, both in vivo and in vitro 126• Consequently, 
viral infection causes a fatal glomerulonephritis in mink due to deposition of soluble 
immune complexes on renal glomerular membrane or wall of capillary blood vessel, which 
causes tissue damage by mononuclear cells and complement and consequently results in 
impairment of renal filtration. Besides formation of soluble immune complexes, ADE of 
infection has also been suggested as a potential contributing factor to the pathogenesis of 
ADV 124;125 _ Initially, Porter et al. found that ADV replicated in macrophages and large 
amounts of non-neutralizing antibody were produced in mink infected with ADV 124 • They 
speculated that the early formation of non-neutralizing antibody might lead to virus-antibody 
complex formation. They further speculated that phagocytosis of these complexes by 
macrophages could lead to increased infection of the cells by ADV resulting in increased 
production of progeny virus. In related work, Porter et al. demonstrated that passive transfer 
of virus-specific antibody at the peak of viral replication resulted in foci of necrosis around 
virus-infected cells. The investigator concluded that this pathological reaction was due to 
enhanced complement-mediated cytolysis, suggesting that antibody has the potential to 
contribute to the severity of disease by ADV 125 • A recent in vitro study by Kano et al. 
demonstrated that infection of mink peritoneal macrophages by ADE is enhanced by anti-
ADV antibody 77 • 
In a trial with an experimental ADV vaccine, the immunization regimen failed to 
produce any detectable neutralizing antibody to ADV. However, following challenge with a 
standardized infectious dose of virus by the oral route, higher levels of circulating antibodies 
were detected in vaccinated mink than in challenged control animals 125 • Moreover, 8 of 10 
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vaccinated mink, but none of control animals, developed Aleutian disease. Cumulatively, 
these observations provide strong evidence that vaccine-induced humoral immunity can lead 
to a more severe disease course through ADE. 
e) Lentiviral diseases 
Equine infectious anemia is a lentiviral infection of horses that generally causes a 
syndrome of fever, anorexia, and anemia with cyclic recurrence during the first year of 
disease. Subsequently, horses may become asymptomatic or develop a chronic wasting 
syndrome. Several studies were conducted to evaluate the efficacy of vaccines against 
equine infectious anemia virus (EIA V) as a model for evaluating AIDS vaccine strategies 
72;168 These studies clearly illustrated that enhanced severity of disease in vaccinated 
animals was due to the presence of vaccine-induced antibody. Issel et al. used viremia as a 
criteria of disease and demonstrated that inactivated whole virus vaccines elicited 100% 
protection against homologous challenge with avirulent EIAV 72 • In contrast the vaccines 
failed to prevent viremia following heterologous challenge with a virulent strain of EIA V. 
However, the vaccine did protect ponies from the subsequent development of clinical 
symptoms after challenge with the virulent strain. Using viremia as criteria of disease these 
investigators also evaluated the efficacy of a subunit vaccine composed of lectin affinity-
purified viral envelope glycoproteins. This vaccine failed to prevent not only viremia but 
also the development of subsequent clinical symptoms following challenge with the 
heterologous virus, while the vaccine provided 100% protection against infection by the 
homologous virus challenge. In a subsequent study, Wang et al. evaluated a recombinant 
subunit vaccine consisting of a baculovirus-expressed surface glycoprotein of EIA V in 
groups of 8 ponies each 168 • Horses immunized with the recombinant vaccine were not 
protected from challenge with either homologous or heterologous strains of EIA V. 
Vaccination resulted in significantly higher levels of viremia that persisted for longer period 
of time. In addition, the severity of disease in vaccinated ponies was greater than in 
unvaccinated controls following challenge with the virulent heterologous strain. 
Exacerbation of disease severity in vaccinated animals has also been observed with vaccine 
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for other members of the lentiviruses 101• 
Feline immunodeficiency virus (FIV) has also been used as a model to study 
lentiviral infection (i.e. HIV-1) for the development of effective vaccines 9;73 • In some 
vaccine trials, viremia developed earlier in cats immunized with recombinant envelope (env) 
protein of FIV than unvaccinated animals after challenge with homologous virus. 
Interestingly, no or low level of FIV-specific antibodies was detected in experimental 
animals 135 • Similar studies utilizing various experimental recombinant vaccines have also 
shown that the animals developed no or poor neutralizing antibodies to the env protein. 
Nonetheless, enhancement of viral infection took place, as the virus load after challenge in 
vaccinated cats was higher than in unvaccinated cats 7;67 . In addition high antibody titers to 
the core protein of FIV have been demonstrated to be associated with enhancement of the 
disease 66 . 
Currently a similar concern about immune-mediated disease enhancement in HIV 
vaccine trials is being raised because ADE of HIV infection in human peripheral blood 
mononuclear cells has been demonstrated in vitro with sera from HIV -infected individuals 
or animals vaccinated with experimental vaccines 15;6o;97 _ 
f) Arteriviruses 
Studies by Christianson et al highlighted the biological significance of ADE related 
to reproductive problems caused by PRRSV infection. Pregnant sows inoculated in utero or 
intramuscularly with PRRSV that was pre-treated with specific serum prior to inoculation 
showed higher virus titers in fetal tissues as compared to animals that received the virus 
alone 28 • Enhancement of infection in late term fetuses could lead to an increased rate of 
abortions, stillbirths or weak-born piglets. In addition, the potential risk for disease 
exacerbation in pigs with antibody of maternal origin was also demonstrated using passive 
transfer of immunoglobulin specific for PRRSV. Pigs injected immunoglobulin at a low 
neutralizing antibody developed higher and longer lasting viremia after challenge than pigs 
received normal swine serum globulin or injected with immunoglobulin containing 
relatively high level of neutralizing antibody 175 . 
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g) Other viral diseases 
Adverse affects of ADE have also been reported in animals vaccinated with 
experimental rabies or influenza virus vaccines. Sikes et al. evaluated a large number of 
licensed and experimental rabies vaccines in monkeys 150• Vaccines were administered 
either 36 and 73 days prior to challenge or within 6 hours after challenge. Monkeys were 
injected with 104-5-105-8 mouse lethal doses of rabies virus into cervical muscles. Monkeys 
vaccinated either before or after challenge, as well as another group of monkeys given with 
anti-rabies serum, died 6-13 days (mean 11 days) after challenge, while 14 of 17 control 
animals died 14-63 days (mean 25 days) after challenge. The investigators subsequently 
coined the term 'early death' phenomenon to describe these observations. The same 
phenomenon has also been demonstrated in mice inoculated intracerebrally with rabies virus 
2-4 days after a rabies vaccine was administered intraperitoneally 11 • Later, it was suggested 
that the 'early death' phenomenon was attributed to ADE of rabies virus infection mediated 
by vaccine-induced humoral immunity 82;129 • 
In work with an experimental influenza virus vaccine, Webster and Askonas found 
that mice inoculated with one or two doses of inactivated whole virus or subunit vaccines of 
influenza virus A/USSR/90/77 (HlNl) showed enhanced growth of influenza virus in the 
lung following intranasal challenge with homologous or heterologous (X-31, H3N2) strains 
at varying intervals after immunization 169 • 
Disease enhancement due to ADE has also been documented in children vaccinated 
against measles virus 14;38;45 ;132 • Some children immunized with formalin-inactivated, alum-
precipitated measles vaccine developed severe, atypical disease following exposure to wild-
type measles virus approximately 2 to 2.5 years and up to 14 years after initial 
immunization. 
2. Contribution to the pathogenesis of virus infection 
The presence of non neutralizing antibodies capable of facilitating virus entry into 
macrophages or cells expressing Fe or complement receptors may contribute to persistence 
by creating a virus reservoir in macrophages 8• Latency of HIV infection has been described 
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to occur via an M phase where the virus escapes by infecting macrophages. However, 
increase in virus load in the blood of patients infected with HIV-1 has been associated with 
complement mediated ADE (C-ADE). This C-ADE activity correlates negatively with 
CD4+ cell counts and usually precedes clinical progression. Szabo and colleagues 
concluded that there should be a switching from neutralizing towards enhancing antibody 
production before the onset of clinical presentation. The enhancing antibodies would be 
expected to be against the immunodominant gp41 of HIV-1 since the level of these are 
higher in symptomatic patients compared to asymptomatic patients 131 ; 161 • 
Other viruses like PRRSV have been shown to localize in the CNS, particularly in 
microglial cells 87 and can persist through a slow replication rate 5• Contrary to this the high 
replicating rate of LDV can establish persistence even when specific cytotoxic T cell 
responses take place 166 • 
F. Conclusions 
Antibody-dependent enhancement of virus infection is a phenomenon that is not 
exclusive to human pathogens but it is also seen involved in the pathogenesis of viruses that 
affect domestic animals and wild life. Vaccination is the best tool available for the 
prevention and control of infectious diseases, although good management practices of farm 
animals and personal or public hygiene are also important measures for this purpose. 
However, as reviewed above, ADE can be a significant obstacle to the development of 
effective vaccines. In such cases, the presence of viral epitopes that can enhance virus 
infection, thus exacerbating disease, should be taken into consideration. Recombinant 
subunit- or DNA vaccines expressing specific neutralizing epitopes can be one approach for 
minimizing such potential risk but special care has to be taken in the selection of the genes 
or peptides used for these to maximize vaccine success in providing protection instead of 
enhancement. Perhaps the development of novel vaccination strategies or vaccine 
formulation may also offer new frontiers in the control of diseases enhanced by antibody. 
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IDENTIFICATION OF PRRS VIRUS EPITOPES ASSOCIATED WITH 
ANTIBODY-DEPENDENT ENHANCEMENT AND 
NEUTRALIZATION OF INFECTION 
A paper to be submitted to Archives of Virology 
Sol M. Cancel Tirado', Liuzhan Yang' , Kyoung-Jin Yoon1•2 
A. Abstract 
Enhanced infection and replication of porcine reproductive and respiratory syndrome 
virus (PRRSV) in the presence of specific antibody has been demonstrated in vitro and in 
vivo, a phenomenon known as antibody-dependent enhancement (ADE). ADE is considered 
to be a significant obstacle to developing effective vaccines for many viruses for which ADE 
has been reported, since virus-specific antibodies of maternal origin or those conferred by 
vaccination can facilitate the entry of virus into target cells, sometimes resulting in increased 
severity of disease. In this experiment, the role of specific PRRS viral epitopes in ADE 
and/or virus neutralization (VN) was assessed in vitro using 14 monoclonal antibodies 
(MAbs) to 4 PRRS viral proteins: nucleocapsid (N), matrix (M), glycoprotein (GP) 5, and 
GP3 . Each MAb represented a distinct epitope on one of these proteins. One-way ADE and 
VN assays were performed in vitro using homologous PRRS virus isolates in the presence or 
absence of each MAb. ADE activity was determined by detecting a significant increase of 
progeny virus yield in porcine alveolar macrophage cultures in the presence of individual 
MAbs. Neutralizing activity was determined by detecting a significant reduction or 
1 Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa 
State University, Ames, IA 
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complete blocking of virus replication in MARC-145 cells in the presence of individual 
MAbs. MAbs could be categorized into 3 groups: enhancing, neutralizing and neither. 
Neutralizing epitopes appeared to reside on the M, GP3 and GP5 proteins. ADE epitopes 
were associated with the N and GP5 proteins. Identification of the epitopes responsible for 
ADE and VN may provide the basis for developing efficacious second-generation vaccines 
for the control of PRRSV. 
B. Introduction 
For over a decade porcine reproductive and respiratory syndrome (PRRS) has been a 
disease of great significance to the swine industry since it first appeared as catastrophic 
clinical outbreaks in swine herds in North America and Europe in the late 1980's l ;3;5; ll ; l 8;78;79 • 
Despite the efforts to control the syndrome, this disease is still present and responsible for 
great economic losses for pig producers throughout the world. 
Clinically, PRRS induces reproductive disorders in pregnant animals and/or 
respiratory disease in pigs of all ages 9;23 ;69;73• Reproductive disease in pregnant animals is 
manifested as late-term abortions or premature farrowings. Affected litters have a higher 
proportion of stillborn and weak born piglets and increased preweaning mortality 25;35 • 
Porcine reproductive and respiratory syndrome is caused by PRRS virus (PRRSV), 
which is a small, enveloped RNA virus that belongs to the family Arteriviridae with equine 
arteritis virus (EA V), lactate dehydrogenase-elevating virus (LDV) of mice, and simian 
hemorrhagic fever virus (SHFV) 7. Although smaller in size and lacking the surface 
projections characteristic of coronaviruses, the arteriviruses are classified in order 
Nidovirales with family Coronaviridae because of common traits in genomic organization 
and replication strategy 7;12;41 • 
The PRRSV has a polyadenylated, single-stranded, non-segmented, positive-sense 
RNA genome of 15.1 kilobases in size 5;12;41 ;42 • The genome consists of 8 open reading 
frames (ORFs) that are expressed through the production of a nested set of 6 sub genomic 3' 
co-terminal mRNAs 5;12;41 ;42 • ORF 1 encodes for the viral RNA-dependent RNA polymerase 
12;41 . ORFs 2 to 7 are postulated to encode for structural proteins, but only 3 proteins have 
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been consistently identified in virions and/or lysates of virus-infected cells. These are the 
l 5kD nucleocapsid (N), l 9kD matrix (M), and 25kD envelope (E or GP5) proteins that are 
encoded by ORFs 7, 6, and 5, respectively 48;49 . Proteins encoded by ORFs 2 to 4 are 
designated GP2, GP3, and GP4, where 'GP' indicates 'glycoprotein' and the number 
designates the ORF from which it is derived. They are postulated to be associated with the 
viral membrane 43;65 • 
The PRRSV possesses four characteristics that may contribute to difficulties in 
diagnosis and control of the disease, including production of effective vaccines 40• These 
are: 1) tropism for macrophage or macrophage-lineage cells 15;32;66 2) remarkable antigenic 
variation among PRRSV field isolates 14;33 3) enhancement of virus infection by the presence 
of antibody, known as antibody-dependent enhancement (ADE) s; l o; 76;77 and 4) ability to 
establish persistent infection 70• Tropism for macrophages is a significant impediment for 
exposed animals to develop effective local and systemic immunity 66• The antigenic 
variability has the potential of rendering useless any preexisting antibody that once was 
capable of neutralizing the virus and permits the development of new strains that can evade 
the immune system or revert to virulence 55 ;67 • ADE can facilitate the attachment and 
internalization of the virus into its host cells, such as macrophages and monocytes, through 
Fe receptor-mediated endocytosis using antibody present at subneutralizing levels 52;58;76 . 
Persistence has significant epidemiological implications related to virus perpetuation in a 
herd and transmission to na'ive animals 24 • 
ADE of virus infection has been described for various viruses belonging to 12 
different families of various taxa and host 16;27;52;56-58;63 ;64;76• Among them are the human 
immunodeficiency virus type 1 (HIV-1 ), Ebola virus, West Nile virus, influenza virus, 
dengue virus (DV), feline infectious peritonitis virus (FIPV), lactate dehydrogenase-
elevating virus (LDV), equine infectious anemia virus, Aleutian disease virus and, foot and 
mouth disease virus, to name a few. ADE plays a role in enhancing the opportunity for 
viruses to infect target cells, and exacerbation of disease due to ADE has also been well 
documented for DV and FIPV infections 6;28 ;29;61;62 . 
ADE has been considered one of the major impediments to the development of 
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efficacious vaccines for certain viruses such as FIPV, DV, and HIV-1 38 ;47;5 1• To minimize 
the risk associated with ADE in controlling disease by vaccination, efforts have been made 
to formulate vaccines inducing a balanced immune response and to identify viral 
component(s) associated with ADE or neutralization of virus infection 38;47 • In addition, 
numerous researchers have studied the mechanisms of ADE, particularly cellular events 
besides simple increased uptake of virus coupled with antibody 50;59 . 
The effectiveness of commercially available vaccines to PRRSV has been questioned 
because of the persistence of the virus in vaccinated herds2;40 . Although many reasons may 
account for the inefficiency of vaccination in controlling the disease or infection, ADE of 
PRRSV infection may be one of those reasons. The following study was conducted to 
characterize the role of PRRS viral proteins in ADE and virus neutralization and identify 
responsible epitope(s), working toward development of a subunit vaccine that would offer 
protection against PRRSV. 
C. Materials and methods 
1. Experimental design 
This study attempted to identify epitope(s) associated with neutralization and/or 
ADE of infection. The role of individual PRRS viral epitopes in ADE and virus 
neutralization was determined using a panel of 14 murine monoclonal antibodies (MAbs) 
specific for various PRRSV proteins. Prior to conducting ADE or VN tests, the 
compatibility between the Fe portion of murine MAb and Fe receptors (FcR) on porcine 
alveolar macrophages (PAM) was tested by a rosette formation assay. The amount of 
PRRSV-specific antibody in each ascitic fluid was measured by indirect fluorescent 
antibody (IF A) test, and adjusted to the same level. Enhancing or neutralizing activity of 
each MAb was then assessed utilizing an in vitro ADE assay and one-way virus 
neutralization test, respectively. Differences in virus progeny production between treated 
and non-treated groups were calculated and statistically compared. 
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2. PRRSV strains 
Two PRRS viruses designated ISU-P and KY-35 were used in ADE and virus 
neutralization (VN) assays. Both isolates were collected from diseased pigs in swine 
operations in Iowa and Kentucky, respectively, and were used as antigens for producing the 
panel ofMAbs used in this study (Table 1). These viruses share most of the epitopes studied 
except those recognized by MAbs ISUl 9C, ISU45Ad and ISU45B. Both viruses were 
propagated in MARC-145 cells, a highly permissive clone of the African Monkey kidney 
cell line MA104 26, and, after titration, aliquoted and kept frozen in minus 80°C until used. 
3. Cells 
Porcine alveolar macrophages (PAM) and MARC-145 cell lines were used. The 
PAM were collected from 5- to 6-week-old piglets free of PRRSV through lung lavage as 
previously described 76 and used for ADE assay. PAM cultures were prepared by quickly 
thawing frozen cells, suspending them in RPMI-1640 (Sigma Chemical Co., St. Louis, MO, 
USA) supplemented with 10% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT), 
50µg/ml gentamicin (Sigma Chemical Co) and an antibiotic-antimycotic mixture composed 
of 100 µg/ml streptomycin, 100 IU/ml penicillin and 25 µg/ml amphotericin B (Sigma 
Chemical Co.), and seeding in multi-well plates. The cells were used after 24-hour 
incubation at 37° Cina humid 5% CO2 incubator. 
MARC 145 cells, were used for virus titrations and VN assays. For use, the cells 
were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma Chemical Co.) 
supplemented with 200mM L-glutamine (GIBCO/BRL Life Science, Grand Island, NY, 
USA), 10%FCS, 50µg/ml gentamicin (Sigma Chemical Co.), and the antibiotic-antimycotic 
mixture. The cells were used for the assays after 24 to 48 hour incubation at 3 7°C in a 
humidified 5% CO2 incubator. 
4. PRRSV-specific monoclonal antibodies 
A total of 14 MAbs specific for PRRSV were obtained as mouse ascites and used in 
the study. Each MAb was specific for distinct epitopes on N, M, GP5 or GP3 proteins. 
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Table 1. Characteristics of PRRSV monoclonal antibodies used 
MAb Specificity IFA titer Homologous Reactivity to MAb tt 
(loglO) virus KY35 ISU-P 
ISU15A 7 ISU-P + + 
ISU15B 7 ISU-P + + 
ISU15C Nucleocapsid 7 ISU-P + + 
ISU15D (15kD) 6 ISU-P + + 
ISU15E 6 ISU-P + + 
ISU15Hdt 6 KY-35 + + 
ISU19Ad 4 KY-35 + + 
Matrix 
ISU19Bd 6 KY-35 + + 
(19 kD) 
ISU19Cd 4 KY-35 + 
ISU25A 5 KY-35 + + 
GP5 
ISU25B 5 KY-35 + + 
(25kD) 
ISU25C 5 KY-35 + + 
ISU45Ad GP3 4 KY-35 + 
ISU45B (43kD) 4 KY-35 + 
t Subfix "d" indicates that given MAb is specific for a discontinuous epitope. 
tt Adapted from Yang et al (2000) 72. Both strains are considered homologous regarding all 
epitopes except ISU19Cd, ISU45Ad and ISU45B MAbs, which are only found in KY-35 . 
Protein specificity and antibody level of each MAb and PRRSV strains used for production 
of MAbs are summarized in Table 1. Production, protein specificity and other 
characteristics of these MAbs have been previously described 71 ;n. All MAbs were oflgG 1 
isotype as determined by a commercial mouse MAb isotyping kit (IsoStrip® Mouse 
Monoclonal Antibody Isotyping Kit, Roche Diagnostic Corporation, Indianapolis, IN, USA). 
Prior to use the total protein amount in each mouse ascites was determined by 
spectrophotometry using a commercial protein assay kit (Total Protein Assay Kit, Bio-Rad 
Laboratories, Hercules, CA, USA) as directed by the manufacturer. The level of PRRSV -
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specific antibody in each MAb was determined by a commercial ELISA kit (HerdCheck® 
PRRS, IDEXX Laboratory, Westbrook ME, USA) and by an indirect fluorescent antibody 
test. The level of antibody in each MAb was then adjusted to the same relative titer 
( approximately 1: 10,000) according to IF A test results. 
5. Indirect fluorescent antibody test 
For the preparation of viral antigen 24-day-old MARC145 monolayers were infected 
with 200µL of a 104 TCID50 viral suspension of ISU-P strain of PRRSV and incubated at 
37°C. Normal cell controls were prepared in the identical manner with cell culture medium 
instead of virus. After 48 hours of incubation the cells were washed twice, with 0.0lM 
phosphate buffered saline (PBS), pH 7.0 and fixed with 80% acetone aqueous solution. A 
series of 10-fold dilution (10 1 to 109) was made with each MAb in PBS. Fifty microliters of 
each MAb dilution were added in triplicate wells and incubated at 37°C for 30 minutes in a 
humidified environment. Unbound MAbs were washed off from wells as above. The 
presence of antigen-antibody reaction was visualized by adding 50µL of goat anti-murine 
IgG conjugated to fluorescein isothiocyanate (FITC, Kirkegaard & Perry Laboratories, Inc., 
Gaithesburg, MD, USA) to each well and performing immunofluorescence microscopy. 
PRRSV-specific antibody titer of each MAb was expressed as reciprocal of the highest 
dilution in which specific fluorescence was observed in all 3 wells. 
6. Enzyme-linked immunosorbent assay 
A commercial ELISA kit (IDEXX Laboratory) was used to determine PRRSV-
specific antibody in each MAb as directed by the manufacturer with two exceptions. Instead 
of anti-porcine conjugate provided with the kit, goat anti-mouse IgG labeled with peroxidase 
(Kirkegaard and Perry Laboratories, Inc.) was used. The presence or absence of specific 
antibody at given dilution was determined using optical density (OD) rather than sample-to-
positive (SIP) ratio. Samples with OD value higher than the upper limit of 95% confidence 
interval of mean OD from normal mouse ascites were considered to be positive for antibody 
to PRRSV. 
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7. Rosette assay 
The compatibility between munne antibody and Fe receptors on porcme 
macrophages was determined by a rosette assay utilizing sheep red blood cells (sRBC) 
coated with murine anti-sRBC polyclonal antibody. Murine anti-sRBC serum was obtained 
from BALB/c mice following a series of intraperitoneal inoculations of 0.5mL of a 50% 
suspension of freshly collected, washed sRBC at a two-week interval, and the level of anti-
sRBC antibody was endpoint titrated by a hemagglutination assay. Antibody-coated sRBC 
were prepared by mixing 1 % (w/v) sRBC suspension with an equal volume of anti-sRBC 
serum at a subagglutinating level and incubating the mixtures for 30 minutes at 3 7° C, then 
an additional 30 minutes at 4° C. 
For the assays, porcine alveolar macrophages (PAM) were prepared in polystyrene 
6cm cell culture Petri dishes (Coming Inc., Coming, NY, USA) at a concentration of 106 
cells per ml of media and incubated in RPMI 1640 medium- supplemented with 10% FCS, 
l0mM HEPES (Sigma Chemical Co.) and the antibiotic-antimycotic mixture for 24 hours at 
37°C in 5% CO2 atmosphere. The cells were gently washed once with PBS and 2ml of 1 % 
antibody-coated sRBC suspension were added. The control cells received the same amount 
of uncoated sRBC. The mixture was incubated for 60 minutes at 37°C and unbound sRBC's 
were removed by rinsing with PBS. The cells were fixed and stained with Diff-Quick 
staining (Difeo Laboratories, Detroit, MI, USA) as directed by manufacturer, and observed 
under 1 00X magnification. A total of 200 cells in randomly selected microscopic fields 
were counted and the proportion of rosette forming cells was calculated. A rosette is defined 
as a macrophage with at least 3 sRBC associated with its membrane. The assay was 
independently repeated three times, and a mean value between treated and control groups 
was calculated and analyzed by Student's t test. 
8. In vitro ADE assay 
Antibody dependent enhancement of PRRSV infection was assessed by measuring 
increases in progeny virus yield as previously described 76• Briefly, PRRSV ISU-P (or KY-
35 for MAbs ISU19C, ISU45A and B) was diluted to a 104 TCID5ofml in FCS-free RPMI 
86 
1640 medium. For test groups, each virus suspension was mixed with an equal volume of 
each of the pre-standardized, serially diluted MAbs (10-1 to 10-1) to be tested. Control 
groups were prepared by mixing each of the viruses with an equal volume of PRRSV-ADE 
positive serum or no antibodies at all in the same manner described above. The virus-MAb 
mixtures were incubated at 37°C for an hour and then 200µL aliquots of each mixture were 
inoculated in triplicates onto PAM prepared in 96-well plates at a ratio of 1 x 104 PAM/well 
24 hours earlier, resulting in 0.1 multiplicity of infection (MOI). After incubation for 1 hour 
at 37°C, the inoculum was replaced with RPMI 1640 medium with 10% FCS, followed by 
an incubation period of 2 days at 37°C. At the end of the incubation period, the cells were 
subjected to 2 cycles of freeze-thawing at minus 80°C and 37°C respectively to disrupt cells 
that may still contain virus. The amount of PRRSV in each cell lysate was quantitated by 
virus titration as described below. 
9. Virus titration 
Each sample containing PRRSV was serially diluted and 100 µ1 of each diluted 
sample was inoculated in triplicates onto confluent MARC-145 monolayers prepared in 96-
well plates 24 to 48 hours earlier. Plates were incubated for 2 to 3 days at 37°C in a humid 
5% CO2 incubator, and then cells were fixed with 80% acetone aqueous solution. The 
presence of PRRSV was determined by staining fixed cells with a cocktail of PRRSV-
specific MAbs SDOWl 7 and SR30 (Rural Technologies, Inc., Brookings, SD, USA). Virus 
titer in each sample was then determined by counting fluorescent foci in wells showing 
between 50 and 100 foci and expressed as fluorescent foci units (FFU) per milliliter. 
10. Virus neutralization assay 
Neutralizing activity of individual MAbs was assessed usmg a fluorescent foci 
reduction assay with KY-35 PRRSV strain. Briefly, a virus suspension containing 
approximately 100 FFU/mL based on pre-determined titer was mixed with an equal volume 
of each standardized MAb. Virus controls were prepared in the identical manner except 
mixing with PRRSV-positive serum or FCS-free minimal essential medium (MEM, Sigma 
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Chemical Co.) instead of MAb. Virus-MAb, virus-serum or virus-medium mixtures were 
incubated for 1 hour at 37°C. After that, 200µL of each mixture were added to triplicate 
wells containing 24- to 48-hour-old confluent MARC-145 cells monolayers in 96 well 
plates. After incubation for 1 hour at 37°C, the inoculum was replaced with fresh MEM 
medium supplemented with 10% FCS and the antibiotic-antimycotic mixture. Then, cells 
were further incubated for 2 to 3 days at 37°C in a humid 5% CO2 incubator. At the end of 
the incubation period, the monolayers were fixed with 80% acetone aqueous solution and 
stained with the anti-PRRSV MAb cocktail. Virus titers in samples treated with individual 
MAbs were expressed as FFU/ml as described above and compared to those in virus control. 
11. Data analysis 
Results of neutralization assays were analyzed by calculating the percent reduction 
(%R) of progeny virus yields (FFUs) in the presence of MAb (fcM) compared to those in the 
absence ofMAb (fcV) with the following formula: 
¾R = 100-[fcM x 100]. fcV 
When reduction of 60% or more in the yield was observed, MAbs were considered to 
possess neutralizing activity. 
Progeny virus yields from ADE assays were determined by calculating FFU/mL for 
all dilutions of each MAb in the assay as well as virus only controls. Due to the work 
volume, progeny virus yields (FFU/mL) were assessed for a set of two or three MAb-treated 
virus groups and one untreated virus control at a time. At a given dilution, geometric means 
of progeny virus yields between MAb-treated and untreated groups were statistically 
compared using Wilcoxon-Kruskal Wallis (Rank Sum) tests. Pair-wise comparisons were 
performed using both Dunnette ' s method and Student's t test using the Bonferroni correction 
to guard against type I error inflation. For all dilutions, data between treated and untreated 
groups were statistically compared by the general regression model 53 • Significance of 
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slopes and intercepts was determined at p s 0.01. 
D. Results 
In the rosette assay, approximately 80% of the PAM counted formed rosettes when 
they were incubated with sRBC coated with murine anti-sRBC antibodies, while less than 
7% of PAM formed rosettes with sRBC pre-treated with normal mouse serum, 
demonstrating that the Fe receptors on PAM can react with the Fe portion of murine 
immunoglobulins (Figure 1 ). 
Each MAb was further characterized for total protein concentration and antibody titer 
through ELISA and IF A, which were needed for standardization among the MAbs to be 
used. IFA antibody titers of individual MAbs ranged from 104 to 107 (Table 1). On ELISA, 
MAbs specific for the N protein (i.e., ISUl 5A to Hd) showed detectable antigen-specific 
response; however, no linear relationship could be obtained between optical densities and 
dilutions ( data not shown). Furthermore, antigen-specific reactivity could not be 
demonstrated on the commercial ELISA with some MAbs, particularly, those specific for M 
and GP5 proteins. Total protein levels of mouse ascites ranged from 21.84 to 32.36 mg/ml 
and did not correlate with antibody levels determined by IF A or ELISA. Thus, MAbs were 
standardized so that all MAbs would have a titer similar to the MAb with the lowest titer 
according to IF A test results, i.e., 104 IF A titer. 
Neutralizing activity of MAbs against PRRSV isolate KY-35 is summarized in 
Figure 2. Monoclonal antibodies specific for the N protein (ISUl 5A to Hd) did not 
neutralize infection of MARC-145 cells by PRRSV. Using 60% reduction in progeny virus 
production as cut off, MAbs ISU19A, ISU25B and ISU45B were determined to have 
neutralizing activity to KY-35. Replication ofKY-35 in MARC-145 was not inhibited when 
the viruses were treated with the remaining MAbs. 
In vitro ADE assays using serially diluted MAbs revealed that MAbs tested at the 
lowest dilution (approximately 103 IFA units) could be categorized into 3 groups: enhancing, 
suppressing and neither (Figure 3). Based on progeny virus yield, significant enhancement 
of PRRSV infection (ps0.01) was observed only with ISU25C, suggesting that the epitope 
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A 
B 
Figure 1. Photomicroscopy of H&E stained porcine alveolar macrophages (PAM) 
exposing to sheep red blood cells (sRBC) pre-treated with murine anti-sRBC serum (A) 
and untreated sRBC (B). Panel A shows rosette formation indicating the compatibility 
between porcine Fe receptor and murine immunoglobulin. Observed under light 
microscope at 20X magnification. 
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Monoclonal antibody 
Figure 2. Relative susceptibility of PRRSV (isolate KY-35) to neutralization by 
monoclonal antibodies (MAbs) specific for distinct epitopes on various PRRSV 
proteins. Numbers in designation represent molecular masses of PRRS viral protein 
for which individual MAbs are specific. FFU stands for foci forming units. Each data 
point represents the mean value of triplicate measurements of each treatment. 
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Figure 3. Production of infectious progeny PRRSV in porcine alveolar macrophages. 
Cells infected with 0.1 MOI virus in the presence of monoclonal antibodies specific for 
distinct epitopes at a rate of approximately 103 IFA antibodies. Each bar represents 
the geometric mean of net progeny virus yield (foci forming units per milliliter) relative 
to untreated control group. Error bars are the standard deviation of the mean. 
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represented by this antibody is associated with ADE of PRRSV infection. Mean virus yield 
from PAM infected with PRRSV in the presence of MAb ISU25C was of 1.5 log 10 higher 
than that from PAM exposed to the virus only. On the other hand, infectivity and/or 
replication of PRRSV in PAMs was significantly suppressed (p::;0.01) after treatment with 
MAbs ISU15B, ISU15Hd, and ISU45B. Mean progeny virus yields were reduced by 0.6 
log10 to 5 log10 relative to those of their respective untreated control group. Neither 
enhancement nor suppression of progeny virus production in P AMs was observed when 
PRRSV was pre-treated with the remaining MAbs. 
Significant enhancing activity (p<0.001) of MAb ISU25C for PRRSV replication 
continued to be present over a series of dilutions, i.e., lower antibody concentration (Figure 
6). In addition, progeny virus yield in P AMs appeared to increase when PRRSV (ISU-P) 
was pre-treated with MAb ISU15E (y = -0.93795 + 0.0008419 dilution, r2=0.1445,p = 0.04) 
at higher dilutions (Figure 4), as was the case with polyclonal anti-PRRSV swine serum 
used as reference (Figure 8). 
Some of the MAbs that significantly suppressed progeny virus production in P AMs 
at the lowest dilution (i.e., ISU15B and ISU45B) retained the same effect on PRRSV 
replication even after their concentration was diluted (Figures 4 and 7). In addition to these 
MAbs, MAbs ISUl 5A, ISUl 9B and ISU25B were determined to significantly suppress the 
production of PRRSV progeny virus in P AMs over a series of dilutions at p::;0.01 (Figures 4 
to 6). In comparison, MAb ISU15Hd did not show suppressing activity at any dilution 
except the lowest. MAb ISU19A was increasingly suppressive on PRRSV replication in 
PAMs over a series of dilutions (y=0.371859 - 0.0014272 dilution, r2=0.3652,p=0.0002). 
E. Discussion 
The present study attempted to identify epitopes associated with ADE of PRRSV and 
those responsible for virus neutralization using a panel of well-characterized MAbs against 
epitopes on various PRRSV proteins. Monoclonal antibodies have been commonly used for 
this purpose since each MAb represents the antigenicity of a single epitope. Furthermore, 
the usefulness of MAbs for this purpose has been proven by other investigators 13; l 9;2 1;45 ;so;59 _ 
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Figure 4. Production of infectious progeny PRRSV in porcine alveolar 
macrophages. Cells were infected with ISU-P treated with monoclonal antibodies 
specific for distinct epitopes of PRRSV nucleocapsid protein. Values represent 
mean difference in progeny virus yields between treated and untreated groups at 
each dilution. Error bars are the standard deviation of the mean. 
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Figure 5. Production of infectious progeny PRRSV in porcine alveolar macrophages. 
Cells were infected with KY-35 (ISU19C) or ISU-P (ISU19A and B) treated with 
monoclonal antibodies specific for distinct epitopes of PRRSV matrix protein. Values 
represent mean difference in progeny virus yields between treated and untreated 
groups at each dilution. Error bars are the standard deviation of the mean. 
95 
4 
-0 
..--
O') 2 0 
C 
....J 
E 0 
---:::) 
LL 
LL 
-
"'O 
-2 Q) 
">-
(/) 
::l 
.... 
·s; 
-4 
>, 
C 
Q) 
O') 
0 
.... 
-6 c.. 
-
----@- IS U 25A 
----©- I SU 2 5 B 
Q) 
z --1::r- I SU 2 5 C 
-8 
20 40 80 160 320 640 1280 2560 
MAb dilution 
Figure 6. Production of infectious progeny PRRSV in porcine alveolar macrophages. 
Cells were infected with ISU-P treated with monoclonal antibodies specific for distinct 
epitopes of PRRSV major envelope protein. Values represent mean difference in 
progeny virus yields between treated and untreated groups at each dilution. Error 
bars are the standard deviation of the mean. 
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Figure 7. Production of infectious progeny PRRSV in porcine alveolar macrophages. 
Cells were infected with KY-35 (ISU45Ad) or ISU-P (SIU45B) treated with monoclonal 
antibodies specific for distinct epitopes of PRRSV GP3. Values represent mean 
difference in progeny virus yields between treated and untreated groups at each 
dilution. Error bars are the standard deviation of the mean. 
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Figure 8. Production of infectious progeny PRRSV in porcine alveolar macrophages. 
Cells were infected with ISU-P treated with serum specific for PRRSV. Values 
represent mean difference in progeny virus yields between treated and untreated 
groups at each dilution. Error bars are the standard deviation of the mean. 
98 
Our study demonstrated that all 14 anti-PRRSV MAbs tested could be categorized into 3 
groups : neutralizing/suppressing (e.g., ISU15A, ISU15B, ISU25B, ISU19A, ISU19B, 
ISU45A, ISU45B), enhancing (e.g., ISU15E and ISU25C), and non-neutralizing/non-
enhancing (e.g., ISU15C, ISU15D, ISU15Hd, ISU19C, ISU25A). This observations 
indicate that individual epitopes of PRRSV may have unique role in ADE and neutralization 
of virus infection, which is in general agreement with reports of previous similar studies on 
other viruses 13 ;21• 
In general ADE of infection by enveloped viruses is believed to be mediated by 
epitope(s) associated with envelope protein or membrane-associated protein(s) 30;36 . Our 
observations with PRRSV MAbs were in agreement with other investigators' observations. 
Epitopes associated with ADE are determined to reside on the l 5kD nucleocapsid and 25kD 
envelope (GP5) proteins, whereas epitopes of the 19kD matrix, GP5 and 45kD GP3 proteins 
were mainly associated with virus neutralization. It is worthwhile to note that MAbs 
ISU25B and ISU45B suppressed PRRSV replication in both MARC-145 cell line and 
P AMs. Involvement of GP5 protein in inducing neutralizing or enhancing antibodies have 
been demonstrated by our laboratory and others 17;31 ;68;72;75 ;76 • It was, however, unexpected 
that an antigenic determinant of the GP3 protein, represented by MAb ISU45B, would be 
associated with inhibition of PRRSV replication. Statistically MAb ISU45B showed much 
stronger inhibition of PRRSV replication in porcine alveolar macrophages, PRRSV natural 
target cells, than MAb ISU25B representing an epitope on the GP5 protein (p<0.01). For 
some North American PRRSV isolates, GP3 protein has been reported as a non-structural 
protein 37• In contrast, it has been described as a structural protein for some European 
PRRSV isolates 44 . A recent study reported that ORF3 product of a Spanish PRRSV strain 
from recombinant Baculoviruses provided pigs with protective immunity against PRRSV 
challenge 54 . Further investigation remains to determine the role of GP3 in PRRSV 
pathogenesis or immunity. 
PRRSV infection was also enhanced or suppressed when treated with MAbs specific 
to epitopes on the nucleocapsid (N) protein (i .e. ISUl 5E enhanced, ISUI 5A and B 
suppressed). These were unexpected observations since no part of the N protein has been 
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demonstrated to be exposed to the outside of intact virions. Theoretically, such observations 
are possible if naked or partially stripped viruses containing intact infectious RNA were in 
the virus preparation used for the assay, which is likely since the virus material used in our 
study was not purified through zonal centrifugation. However, it also has been demonstrated 
that the requirement of intact infectious virions for infection in permissive cells can be 
bypassed through ADE pathway for virus entry 39 • Consequently, our observation on 
ISU15E may have a significant implication in the pathogenesis of PRRSV. The 15kD N 
protein is known to be highly immunogenic, and abundant expression of ORF 7, the gene 
encoding for the N protein, in the early stage of infection has been demonstrated in vitro and 
in vivo 4;34;36;74 . Likewise, it has also been reported that high levels of non-neutralizing 
antibody, most of which is specific for the N protein are produced in pigs following 
exposure 74 . Subsequently, PRRSV could take advantage of ADE for entry to target cells, 
macrophages or macrophage-lineage cells. Nevertheless, as demonstrated in our results, 
some of the anti N antibodies may have a suppressive effect, but as stated above this could 
be related to the presence of naked virus or virions partially stripped from their envelope in 
the virus suspension used in the assay. 
In vitro assessment of ADE activity by antibody can be affected by various factors. 
These include isotype or subtype of immunoglobulin 22 , assay conditions such as virus strain 
(e.g. , homologous versus heterologous), antibody titer, multiplicity of infection 45;46;50 , and 
parameter( s) for measuring enhancement 45 ;46;so;60;62 . All these factors were taken into 
consideration, including isotype determination. All MAbs used were of the IgG 1 subtype, 
thus, any results from ADE or neutralization assays described in the present study are 
independent of the immunoglobulin isotype/subtype and a property intrinsic to the epitope 
bound. However, it should be noted that specific classification of PRRSV MAbs as to their 
role in VN and ADE may not be conclusive for some MAbs, since antibody concentration of 
individual MAbs were adjusted to the same or similar antibody level for quality control of 
the in vitro assays . Previous studies have suggested that PRRSV infection can be inhibited 
or enhanced in the presence of antibody, depending upon the ratio between 
immunoglobulins and available specific epitopes or between antibody molecules and virion 
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numbers 2o;ss;?6;77 _ The same observation was also made in this study with polyclonal anti-
PRRSV swine serum and may be attributed to the fact that an antiserum consists of various 
subpopulations of antibodies each of which represents different specificity, affinity, and 
avidity. Since a MAb represents a single epitope, such a phenomenon was not expected to 
occur. As anticipated, the role of individual MAbs in ADE and VN was distinct as shown 
by the general regression model, except to ISUl 9C. This MAb suppressed PRRSV 
replication when the virus was treated with it at higher concentration (ps;0.01). As antibody 
concentration was lowered by serial dilution the suppressive effect of this MAb disappeared 
and became enhancing, however thn is trend was not considered statistically significant at 
ps;0.01. 
Antibody dependent enhancement of virus infection is a significant obstacle to the 
development of effective vaccines to control certain viral diseases of public health and 
veterinary importance. The ADE of PRRSV infection has been suspected as one of the 
possible reasons for the relative ineffectiveness of vaccination in controlling PRRS. Our 
present study provides the antigenic basis for developing subunit vaccines that would induce 
protective immunity with minimal or no risk for ADE. Characterization of enhancing and 
neutralizing epitopes demonstrated in this study, however, remains to be further studied. 
Future studies are needed to determine the biological significance of our findings . 
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GENERAL CONCLUSIONS 
A. Conclusions 
In this study, we demonstrated that some of the porcine reproductive and respiratory 
syndrome (PRRS) virus structural proteins have unique role in immunobiology of PRRS 
virus. Using a panel of monoclonal antibodies, epitopes that were examined could be 
categorized into 3 groups: enhancing, neutralizing, and enhancing-neutralizing epitopes. 
Some of epitopes examined were not classified into any of these groups. Neutralizing 
epitopes were found to reside on the19kD matrix (M) and 25kD major envelope 
glycoprotein (GP5). ADE epitopes were associated with the N and GP5 proteins. Even on 
the same protein, the role of individual epitopes in ADE and VN was discernible. 
Identification of the epitopes responsible for ADE and VN may provide the basis for 
developing efficacious second-generation vaccines for the control of PRRS virus. Yet, 
genomic sequences corresponding to these epitopes remain to be identified. Animal trials 
will be required to test the biological relevance of our findings. 
B. Future work 
Due to the nature of the technique to develop MAbs, it is quite possible that the 
epitopes recognized are at sites that would not be exposed on the intact virion. The use of 
immunogold electron microscopy (IGEM) can be used to determine if the epitopes involved 
in ADE and neutralization are indeed exposed to the outside of the viral envelope or if their 
recognition is due to damage in the virus envelope. This is especially important in the case 
of N protein enhancing epitopes since it was reported that it is not exposed to the outside of 
the virion. 
Furthermore, the development of deletion mutant clones of PRRSV proteins would 
serve to pin point the location of neutralizing epitopes and what changes in their sequences 
are involved in the generation of ADE epitopes. This knowledge would be used to develop 
subunit vaccines that would confer protective immunity against the PRRSV and avoid the 
generation of enhancing antibodies. Animal experiments should be conducted to test the 
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efficacy of such vaccines as well as longitudinal studies to determine PRRSV persistence 
after the use of the new vaccine. 
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